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“To wrest from nature the secrets which have perplexed philosophers in all ages, to track to their 
sources the causes of disease, to correlate the vast stores of knowledge, that they may be quickly 
available for the prevention and cure of disease – these are our ambitions.” 
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This dissertation explores the astounding biological heterogeneity of acute myeloid leukaemia (AML). 
In three research papers, we study FLT3 length mutated (LM) AML to contribute to the 
characterisation of genetic diversity between patients but also within the same patient as the disease 
develops over time. 
AML is a rare but severe blood cancer for which outcome is poor. In haemato-oncology as in other 
cancer fields, the imaginary of precision medicine is a potent force that provides direction to research 
as well as the development of clinical practice. Specifically, the hope is to tailor cancer management 
by molecular profiling and therapeutic targeting of actionable aberrations. In the case of AML, the 
validity and utility of this approach is an open empirical question. The aim of this dissertation is to 
explore the biological boundaries of precision oncology in the context of AML. I have pursued this 
aim through empirical characterisation of AML as a heterogeneous and dynamic phenomenon (in the 
research papers) and a literature study and theoretical reflection on the relationship between that 
empirical characterisation and available conceptual frameworks of cancer (in the synthesis part of the 
dissertation).  
Somatic mutation theory, tumour evolution theory and cancer stem cell theory were identified as the 
prevailing conceptual frameworks representing variants of explanatory models in AML. These theories 
also provide justification for the clinical approaches related to precision haemato-oncology. The 
synthesis provides an overview of empirical FLT3-LM AML research poorly accounted for by these 
prevailing models, including intra-leukaemic plurality of FLT3-LMs as well as clinico-pathological 
relationships that suggest context-dependency with regards to FLT3-LM properties. Indeed, in Paper 
I we confirm the finding that AML patients may have several FLT3-LMs. In Paper II, we show hitherto 
undiscovered sex differences in genetic profiles of FLT3-LM AML. In Paper III, a single patient is 
followed through the course of his disease to reveal how genetically diverse cell populations may 
initiate leukaemia in animal models. 
These findings pose challenges to the understanding of FLT3-LMs as causal contributors in AML 
pathogenesis. A major conclusion of this dissertation is that somatic mutation theory is not a sufficient 
conceptual framework for AML. Evolutionary perspectives seem called for, and the dissertation 
proposes that a selection-centric perspective to further the understanding and interpretation of FLT3-
LM AML pathogenesis, conceptualising both cancer cells and cancer as dynamic phenomena rather 
than confined entities. Based on this I propose a shift towards characterisation of permissive conditions 





Dette doktorgradsarbeidet utforsker biologisk heterogenitet i kreftsykdommen akutt myeloid leukemi 
(AML). I tre forskningsartikler studerer vi FLT3 lengdemutert (LM) AML og viser at slik heterogenitet 
fins mellom pasienter, men også innenfor samme pasient etter hvert som sykdommen utvikler seg over 
tid. 
AML er en sjelden, men alvorlig form for blodkreft. Også innenfor forskningen på blodkreft råder det 
for tida en visjon om presisjonsmedisin. Denne visjonen preger både forskning så vel som klinisk 
praksis. Håpet er å kunne skreddersy kreftbehandling ved hjelp av molekylær profilering og målretting 
behandling. For AML er nytteverdien av denne tilnærmingen fremdeles et åpent spørsmål. Målet med 
denne avhandlingen er å utforske biologiske forhold i AML som gir begrensninger for 
presisjonsmedisin. Avhandlingen dokumenterer at AML er et heterogent og dynamisk fenomen. Dette 
diskuteres opp mot begrepene og modellene som forskningslitteraturen på feltet anvender for å forstå 
FLT3-LM AML. 
Avhandlingen viser at somatisk mutasjonsteori, tumor-evolusjonsteori og kreftstamcelleteori er de 
rådende forklaringsmodellene i AML. Disse teoriene benyttes også til å legitimere kliniske 
tilnærminger i hemato-onkologi. Avhandlingens kappe gir en oversikt over funn i FLT3-LM AML-
forskningen som vanskelig kan forklares av de nevnte modellene, blant annet intra-leukemisk 
mangfold av FLT3-LMs så vel som klinisk-patologiske forhold som tyder på at egenskapene til FLT3-
LMs avhenger av konteksten mutasjonene befinner seg i. I artikkel I bekrefter vi funnet at AML-
pasienter kan ha flere FLT3-LM-er. I artikkel II viser vi hittil uoppdagede kjønnsforskjeller i genetiske 
profiler av FLT3-LM AML. I artikkel III blir en enkelt pasient fulgt gjennom sykdomsforløpet og vi 
avdekker hvordan genetisk forskjellige cellepopulasjoner fra denne pasienten initierer leukemi i 
dyremodeller. 
Samlet sett utfordrer disse funnene den rådende forståelsen av FLT3-LM som årsak til AML. En 
hovedkonklusjon i avhandlingen er således at somatisk mutasjonsteori ikke gir en adekvat beskrivelse 
av patogenesen av AML. I stedet framstår evolusjonsteoretiske perspektiver som mer lovende. 
Avhandlingen foreslår at et seleksjonssentrert perspektiv kan øke forståelsen av hvordan FLT3-LM 
AML oppstår. Både kreftceller og kreft bør forstås som dynamiske fenomener. På bakgrunn av dette 
foreslår avhandlingen at det gis økt oppmerksomhet mot å karakterisere forhold som tillater at 










PAPER I:  
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This dissertation explores the biological heterogeneity of acute myeloid leukaemia (AML). As 
such, it presents the findings of my doctoral research within and inside of one of the many highly 
specialised fields of biomedicine. Specifically, we – my co-authors and I – have studied details of 
the genetic and phenotypic diversity in AML in which the FLT3 gene is length mutated, i.e., FLT3-
LM AML. 
At the same time, this arguably small world of biological heterogeneity and complexity of a quite 
rare disease is connected to the much larger world of cancer research and cancer treatment, and – 
as will become clear – to general conceptual frameworks for cancer and general visions of what 
medicine is and should become. Specifically, the vision of precision medicine – in the cancer field, 
known as precision oncology – is not only a matter of political imagination and discourse but also 
of concrete choices in everyday biomedical research and clinical practice. In the course of my 
dissertational work, I have come to see ever more connections between the findings in the 
biomedical laboratories and the larger scientific and political issues. These connections go in both 
directions. Notably, “small” empirical findings may have broad theoretical implications. In this 
PhD project, I found it necessary to engage with both of these worlds in order to make sense of 
FLT3-LM AML. The empirical characterisations that we present in Paper I-III called for theoretical 
reflection and interpretation that went beyond the genre of biomedical research papers (and thus 
were included in this synthesis); however, these reflections and interpretations also appeared to 
have implications for how to understand AML, how to understand cancer, and how to evaluate the 
current imaginaries of precision oncology. This synthesis – the part of the dissertation that 
introduces and discusses the three included research papers – is my attempt to make sense in writing 
of the nexus of issues defined by FLT3-LM AML at the smaller end and precision oncology at the 
larger. I will do so in a zigzagging motion. First, some introductory words are needed about cancer 
and precision oncology.  
Worldwide, cancer is a major cause of health impairment and premature death. With the rise in life 
expectancy across the globe, cancer incidence and mortality rates are estimated to increase 
substantially in the decades to come (Global Burden of Disease Cancer Collaboration, Fitzmaurice 
et al. 2018, Global Burden of Disease Causes of Death Collaborators 2018). Efforts aimed at 
improving clinical management of cancer are extensive (Eckhouse, Lewison et al. 2008, van de 
Loo, Trzaska et al. 2012). At the heart of this exertion translational cancer research (Cambrosio, 




shape and gaining traction (Hamburg and Collins 2010, National Research Council (US) 2011, 
Mirnezami, Nicholson et al. 2012, Collins and Varmus 2015, Celis and Heitor 2019). 
Precision oncology adheres to the prevailing conceptual understanding of what cancer is: a clonal 
disease, caused by acquisition and accumulation of genetic alterations in cells, ultimately resulting 
in disruption of normal cell function (Nowell 1976, Vogelstein and Kinzler 1993, Hanahan and 
Weinberg 2000, Garraway, Verweij et al. 2013). On the premise that these molecular events are 
patient specific and at the core of the causality of cancer precision oncology proposes a change of 
cancer management along two dimensions: i) from groups to individuals and ii) from 
morphological to molecular classification. Through identification of causally contributing 
molecular mechanisms the goal is to enable precise disease categorisation, prediction, prevention, 
early detection and targeted treatment; providing the right treatment to the right patient at the right 
time (Mirnezami, Nicholson et al. 2012, Tsimberidou, Eggermont et al. 2014, Collins and Varmus 
2015, Ashley 2016) (Figure 1). 
The integration of precision oncology related approaches in standard patient care is an ongoing 
process, resulting in shifts in diagnostic thresholds, formation of novel disease subcategories and 
adaptation of new treatment strategies (Jameson and Longo 2015). Currently, however, only a 
limited fraction of cancer patients is estimated to benefit from this line of approaches (Marquart, 
Chen et al. 2018). Based on the limited progress so far some investigators and clinicians have even 
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Prasad, Fojo et al. 2016, Marquart, Chen et al. 2018). The tension between the current status of 
precision oncology and the optimism related to future benefits of this strategy is an important 
motivation for this work. In the following sections I will give a brief outline of the emergence of 
precision medicine and precision oncology. Next, I shall introduce FLT3-LM AML as a rare but 
severe disease that is important in its own right and also an interesting case for discussing 
conceptual frameworks of cancer. Most of the synthesis is devoted to an in-depth discussion of 
various empirical features of FLT3-LM AML, including the results of Paper I-III. Finally, I shall 
zigzag back to the broader theoretical issues and discuss the possible implications of my (and 
others’) findings for how to understand and manage cancer. 
	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		
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The advancement towards increased precision in medicine and oncology can be seen as a 
continuation of the direction modern medicine has had since its conception (Le Fanu 2000). A 
recent analysis of ancient Hippocratic texts identified that inter-individual heterogeneity was 
recognised already 2500 years ago. This suggests that individually tailored treatment and medical 
care always has been a fundamental feature of applied medicine (Konstantinidou, Karaglani et al. 
2017). It is, however, only throughout the last two centuries molecular mechanisms underlying this 
inter-individual heterogeneity have begun to be revealed. Technological progress has allowed a 
gradual increase in resolution in the exploration of both human physiology as well as pathology. 
Disease classification systems as well as clinical practices have evolved in close relationship with 
methodological advancements. This development is characterised by gradual shifts in 
dimensionality from the clinical and macro-anatomical organisation and understanding of human 
maladies to tissue centred approaches, followed by increasing attention on cells and subcellular 
components as the origin of pathology (Keating and Cambrosio 2001).  
The concept of “molecular” disease was first put forward in 1949 by Pauling and colleagues in the 
Science paper “Sickle Cell Anemia, a Molecular Disease”. The authors hypothesised the genetic 
basis for the condition, and experimentally explored the aberrant protein product responsible for 
erythrocyte “sickling” (Pauling, Itano et al. 1949). In the decades that followed and up until the 
present genotype-phenotype relationships have been confirmed to account for a myriad of human 
traits and disease phenotypes (Buniello, MacArthur et al. 2019). The idea of precision medicine 
gradually emerged from this body of knowledge. It was, however, in relation to the planning and 
execution of the “Human Genome Project”, formally commenced in 1990, that the vision of 
precision medicine was truly articulated (Collins 1999). The Human Genome Project was a 
milestone in the development of the implicit idea of “precision medicine” into a recognizable 




maintained by experts and policy makers (Jasanoff and Kim 2015, Tarkkala, Helén et al. 2019). 
The goal of the “Human Genome Project”, providing a complete sequence of the human genome, 
was ambitious and required considerable financial and intellectual investment. The legitimacy of 
this publicly funded venture was rationalised through postulations of significant scientific, medical, 
and societal advancements (National Research Council (US) 1988). Francis Collins1 put it like this: 
“Scientists wanted to map the human genetic terrain, knowing it would lead them to previously 
unimaginable insights, and from there to the common good. That good would include a new 
understanding of genetic contributions to human disease and the development of rational strategies 
for minimising or preventing disease phenotypes altogether” (Collins 1999)2.  
Since 1999 the imaginary of precision medicine has matured and expanded beyond its initial scope 
to propose fundamental changes not only in how diseases are to be managed but also to be 
categorised and understood. In 2011 the National Research Council (US) released the report 
“Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New 
Taxonomy of Disease”. Here the authors commend the development of a new taxonomy of human 
diseases, predominantly based on intrinsic biology and causal molecular disease mechanisms rather 
than signs and symptoms (National Research Council (US) 2011). The term “precision medicine” 
has since then rapidly been integrated in the biomedical and biotechnological scientific literature 
(Figure 2) as well as the political, regulatory and public discourse (Blasimme and Vayena 2016). 
The uptake has been substantially intensified by the launch of the “Precision Medicine Initiative” 
by Barak Obama in 2015, aimed at accelerating the translation of biomedical science to improved 
clinical outcomes (Collins and Varmus 2015).  
                                               
1 Francis Collins was director of the National Human Genome Research Institute from 1993-2008 and is currently 
the director of the National Institutes of Health. US. 

































Considered a genetic and molecular disease cancer served as an example of the hypothesised future 
significance of the Human genome project as well as the transition towards a molecular based 
disease taxonomy (National Research Council (US) 1988, National Research Council (US) 2011). 
Precision medicine in relation to cancer management has been characterised by a strong emphasis 
on inter-individual variability of genes, and is often referred to as genomics-driven cancer medicine 
(Garraway, Verweij et al. 2013). Medical strategies related to precision oncology are profoundly 
tied to postulations of genetic causality in cancer development. The idea of a monoclonal origin of 
cancer suggest that the cellular mass of an individual tumour share molecular characteristics 
involved in pathogenesis. Observations of cellular dependency of mutated or aberrantly expressed 
gene-products for both initiation and maintenance of malignant phenotypes support this idea and 
led to the postulation and experimental verification of “oncogene addiction” (Weinstein 2002). 
This provided a strong rational for the possibility of classifying various cancers with respect to 
their molecular origin, as well molecular targeted treatment strategies. The feasibility of this 
approach was confirmed in the early 2000s based on several unprecedented clinical success stories, 
including molecular targeted therapy in chronic myeloid leukaemia (Deininger, Buchdunger et al. 
2005) gastrointestinal stromal tumours (DeMatteo 2002) and a molecular defined sub-group of 
breast cancer (Slamon, Leyland-Jones et al. 2001).  
Identification of shared molecular “drivers” in cancer cells originating from discrete cell-types and 
diverse tissues led to the hypothesis that this approach may be scalable, perhaps even to all cancers 
and all cancer patients (Tsimberidou, Eggermont et al. 2014). Instead of managing cancers in 
accordance with their macro-and microanatomical origin treatment could be guided by genomic 
profiling (Garraway, Verweij et al. 2013). Recently, therapeutic compounds based on molecular 
defined indications rather than tissue or histology, such as pembrolizumab, were subject to 
regulatory approval3 (Lemery, Keegan et al. 2017, Scott 2019). This development can be seen as a 
sizeable stride towards making such an approach become standard of care. 
While tissue agnostic indications strongly enforce the implementation of molecular profiling of all 
cancer patients it has been challenging to demonstrate that broad genetic testing followed by 
rationally selected therapeutic compounds generally lead to superior outcomes compared to current 
evidence-based practices (Le Tourneau, Delord et al. 2015, Stockley, Oza et al. 2016, Massard, 
Michiels et al. 2017, Rodon, Soria et al. 2019, Rothwell, Ayub et al. 2019). Experience from 
                                               
3 In 2017 U.S. Food and Drug Administration (FDA) provided approval of a programmed death 1 (PD-1) inhibitor 
(pembrolizumab) for patients with microsatellite-instability–high or mis-match-repair–deficient solid tumours. This 
was followed by the authorisation of a tropomyosin kinase receptor inhibitor (larotrectinib) for cancer patients with 




multiple trials as well as general estimates suggest that currently only a small percentage of cancer 
patients with advanced stage disease are eligible and will benefit from genome-informed therapy. 
Furthermore, the magnitude of clinical benefit that can be attributed to biomarker matched 
interventions is sobering. So far, it is a matter of additional months of life (Marquart, Chen et al. 
2018, Sicklick, Kato et al. 2019), rather than years or decades, as has been achieved in chronic 
myeloid leukaemia, gastrointestinal stromal tumours and some patients with breast cancer (Slamon, 
Leyland-Jones et al. 2001, DeMatteo 2002, Deininger, Buchdunger et al. 2005). 
The limited benefit of precision oncology may in part be accounted for by lack of knowledge as 
well as restrictions in technology, availability of therapeutic compounds and investigation in 
suboptimal study populations. Discovery of novel targets, development of better technological 
solutions, increased availability of therapeutic compounds, improved clinical infrastructure, and 
therapeutic repositioning to earlier disease stages may all contribute to further progress of this 
approach. However, more than 20 years have passed since precision oncology related approaches 
were first projected to result in substantial benefit (Collins 1999). Based on the current discrepancy 
between the promises and 20 years of experience with precision oncology it seems timely to re-
explore the theoretical foundations of precision oncology. 
!		
My dissertation explores certain features of acute myeloid leukaemia (AML). Cancers of the 
haematopoietic system are relatively infrequent (Global Burden of Disease Cancer Collaboration, 
Fitzmaurice et al. 2018). AML, for example, has an age-standardised incidence rate estimated to 
be 3.62 per 100 000 (Sant, Allemani et al. 2010). Still, the discipline of haemato-oncology is 
important as it pioneered and set directions for oncological research and medical oncological 
practice since the early 1950s. The first randomised comparative clinical trial was performed in 
leukaemia (Frei, Holland et al. 1958), and both chemo-therapeutics, combinational regimes 
(Chabner and Roberts 2005), adaptive cell- and immune-therapy (Singh and McGuirk 2016) and 
more recently gene-therapy (Rosenbaum 2017) were all first explored and developed in patients 
with cancers of the blood. The first major breakthrough in the application of precision therapy also 
derives from haemato-oncological practice with the introduction of all-trans-retinoic-acid in acute 
promyelocytic leukaemia (Wang and Chen 2008), a therapeutic strategy developed over 30 years 
ago. Subsequently, the proof of concept for molecular targeted therapy was obtained for chronic 
myeloid leukaemia. The molecular framing of this disease, based on the identification of the 
Philadelphia chromosome and the functional characterisation of the BCR-ABL fusion protein 
(Nowell and Hungerford 1961, Deininger, Buchdunger et al. 2005) resulted in the development of 




improvements of outcome for this patient group (Deininger, Buchdunger et al. 2005). Haemato-
oncological diseases have also frequently provided paradigmatic empirical examples to support 
prevailing theories of cancer, including somatic mutation theory, tumour evolution theory (Nowell 
1976), and cancer stem cell theory (Bonnet and Dick 1997). Furthermore, the diversity and 
contrasts within haemato-oncology makes it a hugely interesting field. Above all, the contrast 
between the success of targeted therapy in acute promyelocytic leukaemia (Wang and Chen 2008) 
and chronic myeloid leukaemia (Deininger, Buchdunger et al. 2005) and the lack of sizeable 
therapeutic progress in AML (Short, Rytting et al. 2018) poses both scientific and clinical 
challenges. In this regards FLT3-LM AML is of particular interest. Descriptively and functionally 
FLT3-LM AML shares some resemblance to BCR-ABL positive chronic myeloid leukaemia. As 
myeloid malignancies AML and chronic myeloid leukaemia derive from related cell populations, 
and they both appear to be driven by genetic aberrations that result in constitutive activation of 
tyrosine kinases. Encouraged by the success of BCR-ABL targeted therapy, FLT3 was very early 
singled out as an attractive therapeutic target in AML (Gilliland and Griffin 2002, Kelly and 
Gilliland 2002, Levis and Small 2003, Stirewalt and Radich 2003). The FLT3 protein is druggable 
and throughout the last two decades considerable effort has been devoted to the development of 
therapeutic agents specifically inhibiting the activity of FLT3. Multiple small molecule inhibitors 
have been demonstrated to induce anti-leukaemic responses in preclinical models as well as in 
clinical trials4 (Engen, Wergeland et al. 2014). Despite this fact FLT3 inhibition has not been able 
to provide more than transient anti-leukaemic responses and marginal clinical benefits, both when 
administered as monotherapy as well as in combination with chemotherapeutic agents (Kindler, 
Lipka et al. 2010, Stone, Mandrekar et al. 2017, Cortes, Khaled et al. 2019). In addition to its 
importance to current and future AML patients, the resistance of FLT3-LM AML to molecular 
clinical approaches makes it a challenging test case for precision oncology. 
                                               
4 Response criteria in AML: Complete remission is defined by reduction of bone marrow blasts to less than 5% as well 
as recovery of haematological function. Additional criteria include absence of circulating blasts, Auer rods and 
extramedullary disease. Complete response without minimal residual disease further requires clearance of leukemic 
cells as assessed by a genetic test or by flow cytometry. Complete remission with incomplete haematological recovery 
is achieved when the criteria of complete remission are fulfilled but signs of bone marrow failure persist. To fulfil the 
criteria of morphologic leukaemia-free state bone marrow blasts must be less than 5%, while bone marrow cellularity 
is at least 10%, in the absence of circulating blasts, Auer rods as well as extramedullary disease. A partial remission 
can be considered achieved by reduction of bone marrow blast percentage by at least 50% as compared to the blast 
percentage prior to treatment. In trials stable disease may also be included as a response criterion. It is applied when 







As is usual for medical doctorates at the University of Bergen, I have chosen to address my research 
questions through a set of (three) research papers that address specific empirical matters, and a 
synthesis that interprets the empirical findings in light of a broader theoretical discussion. In my 
case there has been a need not only to discuss the findings within what might be called the 
prevailing research paradigm in which the individual papers are being published, but also to engage 
in a critical discussion of this paradigm and discuss the significance of my findings for this critique, 
and vice versa. Accordingly, for the synthesis part of the thesis, I have made an attempt not only 
to summarise and review the main knowledge claims at the forefront of haemato-oncological 
research but also to develop a systematic characterisation of this research literature as a discourse, 
in order to be able to criticise it with some rigour. In this section I will describe the methodological 
approach used in the literature study underlying the synthesis. 
A key premise of the vision of precision medicine is that its medical practices are expected to be 
in close correspondence to the understanding of pathophysiological mechanism. This is what is 








































































































































































































































































































































































































have examined the conceptual emphasis with regards to AML pathogenesis in haemato-oncological 
research. Specifically, I reviewed the most cited scientific literature on AML published since the 
year 20005 (Figure 3). Assuming that the number of citations reflects scientific impact in the AML 
research field as well as clinical haematology, I retained papers cited more than 100 times and 
procured these publications for qualitative assessment. The PubMed IDs (PMID) for the final list 
of papers is provided in supplementary table 1. I categorised the papers with respect to thematic 
content and in accordance with explicitly or implicitly articulated conceptual frameworks rationally 
anchoring the knowledge generated. I further identified articulations related to the clinical 
applicability of the research with particular attention on precision medicine related approaches. A 
total number of 254 publications were included in the analysis after exclusion of papers not directly 
related to the AML research field or papers with a predominant focus on methodological 
development.  
The body of literature was strongly dominated by biomedical reports, with a strong emphasis on 
translating biomedical knowledge to medical practice. Papers focusing on molecular profiling of 
AML were prevailing, followed by experimental papers exploring basic biology or drug 
development in pre-clinical AML model systems. Relatively few papers reported outcomes from 
clinical trials. The literature selection further included several review papers in addition to a couple 
of epidemiological reports and meta-analyses.  
The remaining introduction of this thesis is structured in accordance with main themes identified 
across the literature analysis. I start by giving a brief introduction to AML and the FLT3 gene and 
the FLT3 protein. I precede by presenting an outline of the prevailing theoretical frameworks of 
AML pathogenesis as identified in the literature, incorporating observational and experimental data 
from the study of FLT3-LM AML. I then provide a summary of the principal precision medicine 
related approaches in AML and I explore how they relate to theoretical assumptions. 
			
A constant move towards increased resolution is clearly evident in the study and management of 
cancers of the blood. Leukaemia was first described as a distinct clinical entity in the middle of the 
19th century. Initially the disease was recognised based on autopsy findings and later by symptoms 
                                               
5 In detail the 02.05.2019 I queried the PubMed database with the phrase (acute myeloid leukaemia[Title/Abstract]) 
OR (acute myelogenous leukaemia[Title/Abstract]) OR (acute myelogenous leukemia[Title/Abstract]) OR 
(AML[Title/Abstract]) OR (acute myeloid leukemia[Title/Abstract]) and retrieved search results from the period 2000 
to 2019, identifying a total of 32703 unique entries. Median number of PubMed Central (PMC) article citations per 
paper was 2, with a total of 8787 papers with no citations and 320 papers cited more than 100 times. The maximum 




and distinct clinical and biochemical observations. Based on this level of resolution leukaemia 
could be divided in two subgroups: an acute, storming and rapidly lethal form of the disease, 
contrasted by a more indolent, chronic form of leukaemia. Only when microscopic assessment of 
the blood was available by the middle of the 19th century did one approximate the nature of 
leukaemia as a neoplastic condition originating in the haematopoietic system. Based on 
morphological distinctions leukaemia was subjected to additional stratification: leukaemia 
originating from cells committed to the myeloid lineage of the haematopoietic system as opposed 
to leukaemia deriving from the lymphatic cell lineages (Kampen 2012). Founded on morphological 
and cytochemical attributes further sub-classifications followed, and by 1976 three groups of acute 
lymphoblastic leukaemia and six distinct morphological subgroups of AML were proposed 
(Bennett, Catovsky et al. 1976) (Figure 4). Simultaneously, the clonal origin of leukaemia was 
suggested, and studies explored the relationships between disease phenotype, cell of origin and 
genetic alterations (Nowell 1976). This perspective gave rise to a shift from a descriptive, 
morphologically based system for organising the different sorts of leukaemia to a more 
pathophysiological and functionally founded organisational structure, frequently based on genetic 
aberrations (Harris, Jaffe et al. 2000, Vardiman, Thiele et al. 2009, Arber, Orazi et al. 2016).  
In line with this development of increasing stratification, AML is currently understood as a 
collective term, congregating a heterogenous group of various acute blood cancers, 
morphologically and clinically characterised by interference with normal haematopoietic 
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M0      Undifferentiated acute myeloblastic leukaemia
M1      Acute myeloblastic leukaemia with minimal maturation
M2      Acute myeloblastic leukaemia with maturation
M3      Acute promyelocytic leukaemia
M3      Acute myelomonocytic leukaemia
M4      Acute myelomonocytic leukaemia with eosinophilia
M5      Acute monocytic leukaemia
M6      Acute erythroid leukaemia




organisation by expansion of myeloid haematopoietic progenitor cells at the expense of normal 
haematopoietic differentiation and maturation.  
AML affects individuals of all ages, but predominantly presents late in life, at a median age of 72 
years (Juliusson, Antunovic et al. 2009). Diagnosis usually follows identification of a relative 
increase of immature blood cells (blast) by examination of a bone marrow smear6, obtained based 
on suspicion of haematopoietic involvement in clinical disease presentation. The disease history is 
usually brief, and the symptoms generally reflect the underlying process of expansion of immature 
cells and bone marrow failure. Common signs of presentation include anaemia, leukopenia and 
thrombocytopenia, occasionally accompanied with extramedullary disease involvement like tissue 
infiltration of leukaemic cells (Estey and Dohner 2006, Dohner, Weisdorf et al. 2015, Short, 
Rytting et al. 2018). 
The natural course of AML is characterised by rapid disease progression which results in death, 
usually within a few weeks to a couple of months from the time of diagnosis (Oran and Weisdorf 
2012). Outcome can be improved by therapeutic intervention, and current treatment options in 
AML include chemotherapy-based regimens, haematopoietic stem cell transplantation, and 
targeted treatment, as well as more lenient disease stabilising treatment plans and supportive care 
(Dohner, Estey et al. 2017). 
#"$				%	
Despite the fact that the natural and uninterrupted advancement of AML is generally predictable, 
the response to available AML treatment regimens vastly differs, resulting in diversification of 
outcome in AML (Dohner, Estey et al. 2010, Dohner, Estey et al. 2017). The probability of discrete 
treatment responses corresponds to patient specific features like age and patterns of disease 
presentation (e.g. AML development following treatment with chemotherapy or AML progression 
from an antecedent myeloproliferative condition) (Appelbaum, Gundacker et al. 2006), but also 
relates to molecular characteristics like cytogenetic aberrations (Grimwade, Walker et al. 1998, 
Grimwade, Hills et al. 2010) and molecular genetic features (Schlenk, Dohner et al. 2008, Patel, 
Gonen et al. 2012, Papaemmanuil, Gerstung et al. 2016). The literature review revealed that this 
variability of outcome most commonly is interpreted as expression of discrete biological disease 
entities. 
                                               
6 AML diagnosis requires a bone marrow blast count of 20% or more. Exceptions include cases where t(15;17), t(8;21), 
inv(16), or t(16;16) are identified. Under such circumstances identification of the translocation is sufficient for 




The single most frequently mutated gene in AML is FLT37 (Cancer Genome Atlas Research 
Network 2013, Tyner, Tognon et al. 2018), and the mutation status of this gene is well recognised 
to predict disease outcome in AML (Daver, Schlenk et al. 2019). This is also the single most 
frequently mentioned gene in the literature selection, underscoring the position of this gene in the 
AML research field.  
The FLT3 gene and the corresponding protein product was first discovered, isolated and described 
in the early 1990s by two independent groups (Matthews, Jordan et al. 1991, Rosnet, Marchetto et 
al. 1991, Rosnet, Mattei et al. 1991, Rosnet, Schiff et al. 1993). The gene, located at chromosome 
13, band q12.2, comprises a total of 96 982 base pairs, distributed across 24 exons and 
corresponding introns, with an estimated protein size of a total of 993 amino acid residues 
(Schnittger 2005). Structurally the gene shares resemblance to cKIT, CSF1R and PDGFR, and it is 
classified as a member of the class III tyrosine kinase receptor family. This is a group of trans-
membrane cytokine/growth factor receptors, characterised by an extracellular ligand-binding 
domain and an intra-cellular tyrosine kinase domain (Figure 5 and Figure 6).  
Gene and protein expression studies have demonstrated that FLT3 predominantly is expressed in 
haematopoietic tissue, including early progenitors of both myeloid and lymphatic linages 
(Matthews, Jordan et al. 1991, Rosnet, Schiff et al. 1993), suggestive of a ligand dependent role in 
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growth and differentiation processes (Lyman, James et al. 1993). This was confirmed by functional 
assessment, demonstrating that FLT3 is an enzyme involved in the maintenance of adult 
haematopoiesis. Binding of its ligand, FLT3-ligand, is normally followed by a conformational 
change, and subsequent activation of the intrinsic tyrosine kinase domain. This results in initiation 
of multiple intra-cellular signalling pathways through phosphorylation of mediator molecules. 
FLT3 signalling has been shown to play a key role in the maturation of monocytes, macrophages 
and dendritic cells (Tsapogas, Mooney et al. 2017). FLT3-ligand has further been shown to be 
upregulated under conditions of haematopoietic stress, suggesting that FLT3 signalling is a central 
mediator of haematopoietic expansion under conditions of demand (Lyman, Seaberg et al. 1995, 
Wodnar-Filipowicz, Lyman et al. 1996).  
FLT3 was already in 1992 suggested to be involved in leukaemogenesis when high expression was 
found in most AML cases, in a substantial fraction of acute lymphoblastic leukaemia of both T- 
and B-cell origin, as well as in chronic myeloid leukaemia blast crisis (Birg, Courcoul et al. 1992). 
In 1996 Nakao and colleagues made a key discovery while studying FLT3 mRNA expression in 
adult leukaemia patients. They discovered that 5 of 30 examined mRNA specimens presented with 
transcripts that exceeded the anticipated polymerase chain reactions amplified product. Sequencing 
of these transcripts revealed that they all contained length mutations (LMs) as partial internal 
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domain 18 (Nakao, Yokota et al. 1996). This finding was validated in larger cohorts of AML, 
demonstrating that FLT3-LMs occur in a considerable proportion of adult AML and acute 
promyelocytic leukaemia patients (Yokota, Kiyoi et al. 1997). FLT3-LMs have subsequently been 
shown to be prevalent in both paediatric AML and acute lymphoblastic leukaemia, although with 
lower frequency than among adults (Xu, Taki et al. 1999). FLT3-LM have additionally been 
described in myelodysplastic syndrome (Meshinchi, Woods et al. 2001), and more recently in 
blastic plasmacytoid dendritic cell neoplasms (Pagano, Valentini et al. 2013).  
Further examination of the FLT3 gene in haematological cancers led to the identification of 
additional types of genetic aberrations, including several FLT3 somatic non-synonymous/missense 
mutations, most frequently located in the tyrosine kinase domain 1 (TKD) region, with D835Y 
being the most frequent variant (Yamamoto, Kiyoi et al. 2001), but also described in the 
juxtamembrane domain (Reindl, Bagrintseva et al. 2006). Insertions, deletions and FLT3 
rearrangement have also been described (Deeb, Smonskey et al. 2014, Chung, Hou et al. 2017, 
Zhang, Paliga et al. 2018), and non-ITD, non-TKD FLT3 mutations have recently been reported in 
myelodysplastic syndrome, myeloproliferative neoplasms (Higgins, Mangaonkar et al. 2018) and 
in acute lymphoblastic leukaemia (Zhang, Zhang et al. 2019). 
!			"	
The literature analysis performed for the synthesis part of this dissertation indicated that current 
understanding of AML is founded on several intersecting and complementary theories of cancer. 
On the whole, the explanatory narratives identified contained details specific to AML. Still, as one 
might expect, they also strongly resembled prevailing general theoretical frameworks of cancer, 
including somatic mutation theory, tumour evolution theory, and cancer stem cell theory. In the 
following pages, I shall describe and discuss how these frameworks are included, presented and 
interpreted in the empirical knowledge base of AML, and in particular FLT3-LM AML, with 
respect to disease causality, leukaemic development and cellular origin. Before entering into these 
details, however, I present a brief historical account of the general theoretical frameworks (or 
“models”) of cancer. 
The somatic mutation theory was first proposed by the German biologist Theodor Boveri in the 
seminal paper “Frage der Entstehung maligner Tumouren”, published in 1914 (Boveri 2008). 
Based on observations of the development of sea urchin eggs he put forward a theory suggesting 
that cancer formation is clonally derived from a single somatic cell and results from genetic 
                                               
8 ITDs in the FLT3 gene frequently also involve small insertions. I thus refer to FLT3-LMs: comprising FLT3-ITDs, 




damage. Tumour evolution theory, the idea of cancer as a disease that develops over time in 
multiple steps, was later articulated and conceptualised by the Finnish historian and architect Carl 
O. Nordling in a paper published in the British Journal of Cancer in 1953. The theory was founded 
on analysis of epidemiological data with focus on the relationship between age distribution of 
cancer presentation and exposure of mutagens. The result suggested that cancer is the outcome of 
a process that takes several years and sometimes even decades to develop to clinically overt disease. 
These two ideas, somatic mutation theory and tumour evolution theory, only really gained traction 
after the identification of specific recurring oncogenes, including the Philadelphia chromosome 
(Nowell and Hungerford 1961). A unification of the two models was subsequently put forward by 
Peter Nowell in the landmark paper “The clonal evolution of tumor cell populations”, published in 
Science in 1976. Based on the previously developed theoretical frameworks and supported by his 
own observations and experimental results Nowell synthesised that cancer has a monoclonal origin 
and results from a stepwise accumulation of somatic mutations, ultimately giving rise to a 
malignant phenotype (Nowell 1976). At the same time theories of the cellular origin of cancer were 
put forward. Since cancer evolves over time and through progressive steps John Cairns postulated 
that the cell of origin must be long lived and characterised either by pre-existing or acquired self-
renewal properties. Only mutations in persistent long-lived cells endure and only mutations in cells 
which divide and produce progeny emerge (Cairns 1975).  
From the reviewed literature it was possible to identify and formulate a view that integrates the 
three models of somatic mutation theory, tumour evolution theory and cancer stem cell theory. 
While it would be too strong to characterise this view as a consensus, the reviewed literature was 
largely consistent with it. In this view, AML development is understood as the manifestation and 
gradual dominance of a novel aberrant cell population. This cell population is assumed to descend 
from a single haematopoietic stem or progenitor cell that as a result of sequential acquisition and 
accumulation of somatic mutations has progressed through a stepwise process resulting in the 
emergence of properties like differentiation block, autonomous proliferation and immortality 
(Figure 7).  
In the following sections I will explore the knowledge base supporting these conceptual 
frameworks and I will interconnect them to the FLT3-LM AML literature with emphasis on the 
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The main assumptions of somatic mutation theory are i) that any cancer has a monoclonal origin 
and ii) that the acquisition of somatic mutations is the main cause of cancer development. The 
monoclonal origin of cancer was originally explored in studies of X-inactivation patterns in females 
where most cancers were shown to be characterised by a single X-inactivation pattern (Fialkow 
1972, Vogelstein, Fearon et al. 1987). Subsequent identification of cytogenetic and molecular 
aberrations shared across all cells of individual tumours, including AML, provided further support 
of a shared unicellular ancestry (Kelly and Gilliland 2002, Mrozek, Heerema et al. 2004, Frohling, 
Scholl et al. 2005).  
Recurrence of genetic aberrations of single genes has provided support to the idea of genetic causal 
contribution in cancer and in AML. Currently, more than 30 individual genes are recognised to be 
repeatedly mutated in AML, of which FLT3 is the most commonly mutated. Combining single 
nucleotide variants and LMs, FLT3 is mutated in up to 30-40% of adult AML patients (Cancer 
Genome Atlas Research Network 2013, Metzeler, Herold et al. 2016, Tyner, Tognon et al. 2018). 
Furthermore, most of the genes recurrently mutated are known to be important regulators of cell-
identity and cell-fate, including genes involved in DNA methylation, cohesin complex formation, 
transcription, post-translational modification, as well as cell signalling enzymes and well known 
tumour suppressor genes (Cancer Genome Atlas Research Network 2013). The single most 
common group of genes mutated in AML are signalling genes, further strengthening the plausibility 
that FLT3 mutations are causally implicated in leukaemogenesis (Cancer Genome Atlas Research 
Network 2013).  
Relationships between genotypes and phenotypes, including outcome, have supported the genetic 
emphasis in cancer causality, proposing that genetic damage not only results in disease but in 
specific disease phenotypes. The detection of FLT3-LMs in primary patient material has been 
shown to be statistically associated with clinical, pathological as well as molecular features in 
AML. In detail positive FLT3-LM status has been associated with clinical features like leucocytosis 
and high bone marrow blast percentage at time of diagnosis (Kiyoi, Naoe et al. 1997, Kottaridis, 
Gale et al. 2001, Schnittger, Schoch et al. 2002). Positive FLT3-LM status has further been 
correlated with cytomorphological features along the myeloid differentiation axis (Thiede, Steudel 
et al. 2002) as well as with normal cytogenetics (Schnittger, Schoch et al. 2002, Thiede, Steudel et 
al. 2002) and mutations in genes like NPM1 and DNMT3A (Cancer Genome Atlas Research 
Network 2013, Garg, Nagata et al. 2015, Tyner, Tognon et al. 2018). Expression of certain 
immuno-phenotypical markers (Munoz, Aventin et al. 2003, Rausei-Mills, Chang et al. 2008, 
Chauhan, Ihsan et al. 2013), intra-cellular signalling patterns (Irish, Hovland et al. 2004), gene 




Whitman, Maharry et al. 2010) and long non-coding RNA profiles (Papaioannou, Nicolet et al. 
2017), as well as chromatin accessibility configurations (Cauchy, James et al. 2015) have all been 
associated with positive FLT3-LM status. Identification of FLT3-LMs further indicate poor 
prognosis across several outcome indicators, including high likelihood of poor treatment response, 
high relapse rate, and inferior event-free, disease-free and overall survival (Kiyoi, Naoe et al. 1999, 
Abu-Duhier, Goodeve et al. 2000, Kottaridis, Gale et al. 2001, Meshinchi, Woods et al. 2001, 
Frohling, Schlenk et al. 2002, Schlenk, Dohner et al. 2008, Patel, Gonen et al. 2012).  
Expression of FLT3-LMs in cellular model systems have demonstrated ligand independent 
dimerization and phosphorylation at the tyrosine residues, suggestive of gain-of-function properties 
(Kiyoi, Towatari et al. 1998, Kiyoi, Ohno et al. 2002). Introduction of FLT3-LM in growth factor 
dependent cell lines results in growth factor independency (Hayakawa, Towatari et al. 2000, 
Mizuki, Fenski et al. 2000, Zheng, Friedman et al. 2002). FLT3-LMs have further been shown to 
result in qualitative signalling alterations (Schmidt-Arras, Bohmer et al. 2009) through abnormal 
activation of at least three major intra-cellular pathways important for normal cell function: 
PI3K/AKT/mTOR, RAS/RAF/MEK/ERK/ and JAK/STAT (Gotze, Ramirez et al. 1998, 
Hayakawa, Towatari et al. 2000, Irish, Hovland et al. 2004, Kornblau, Womble et al. 2006, 
Choudhary, Brandts et al. 2007, Sanz, Burnett et al. 2009). The causal contribution of FLT3-LM 
has additionally been reinforced by demonstration of FLT3 dependency in FLT3-LM AML 
samples. Under in vitro conditions and in animal models over a dozen different tyrosine kinase 
inhibitors have shown anti-leukaemic effects, in support of oncogene addiction (Levis, Tse et al. 
2001, Levis, Allebach et al. 2002, Weisberg, Boulton et al. 2002, Fathi and Levis 2011). This has 
further been supported by induction of clinical responses following treatment with FLT3 inhibitors 
in FLT3-LM positive patients (Smith, Levis et al. 2004, Stone, DeAngelo et al. 2005, Fischer, Stone 
et al. 2010). Disease progression characterised by addition of FLT3 mutations conferring tyrosine 
kinase inhibitor resistance corroborates the conclusion that FLT3-LMs are important “drivers” in 
AML development (Smith, Wang et al. 2012).  
	
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While many recurrent cancers are strongly related to lifestyle, environmental exposure, or viral 
infections (Danaei, Vander Hoorn et al. 2005) AML is only weakly associated with identified risk-
factors. Although smoking and exposure to radiation, alkylating chemotherapy, topoisomerase II 
inhibitors or substances like benzene are known to increase the likelihood of AML presentation, a 
history of such exposure can be identified only in a minor fraction of AML cases (Shallis, Wang 
et al. 2019). On the contrary several medical conditions, both congenital and somatic, are known 




myelodysplastic syndrome, and myeloproliferative neoplasms (Deschler and Lubbert 2006). A 
multistep model of leukaemogenesis accounts for the latency between exposure and AML 
presentation. It further provides explanatory power, accounting for how germline variants or 
predisposing conditions increase the risk of AML, essentially as interrelated conditions evolving 
from the same underlying pre-leukaemic process.  
In Nowell´s paper on tumour evolution he presented human leukaemogenesis as an example of a 
process characterised by relatively few “steps” (Nowell 1976), and until the 1990s the multistep 
genesis of AML remained controversial. Based on observations of persisting clonal cells in 
nonlymphocytic leukaemic remission Fialkow and colleagues established that also AML progress 
from a preleukaemic phase (Fialkow, Janssen et al. 1991). This was further supported by 
observations of persisting chromosomal aberrancies in AML remission (Miyamoto, Nagafuji et al. 
1996), and more recently by residual cells characterised by AML related molecular somatic 
variants (Corces-Zimmerman, Hong et al. 2014, Ploen, Nederby et al. 2014).  
In AML the prevailing theoretical fundament for understanding disease development is an 
expansion of tumour evolution theory which derives directly from the study of FLT3-LM AML. 
Gilliland and Griffin put forward a "2-hit" model of AML pathogenesis in a review paper titled 
“The roles of FLT3 in haematopoiesis and leukaemia” published in 2002. They suggested that 
AML development both necessitates and suffices two “hits”: differentiation impairment (class 2 
Class I Mutations:
Confer proliferative and/or
survival advantage, but do not
affect differentiation
  - FLT3-ITD
  - FLT3 D835Y
  - N-RAS
  - K-RAS
Class II Mutations:
Serve primarily to impair
hematopoietic differentiations
and subsequent apoptosis
  - PML/RAR-alpha 
  - AML1/ETO
  - CBF-beta/SMMHC



















mutations) in addition to acquisition of proliferative and/or survival properties respectively (class 
1 mutations), arguing for FLT3-LMs as a model for the later class of mutations (Gilliland and 
Griffin 2002) (Figure 8). The advent of next generation sequencing has rapidly enhanced the 
resolution of the genetical landscape of AML, expanding on the model. In 2008 and 2009 the first 
reports describing whole AML genomes were published (Ley, Mardis et al. 2008, Mardis, Ding et 
al. 2009), and over the last decade several large AML sample cohorts have been profoundly 
genetically characterised (Welch, Ley et al. 2012, Cancer Genome Atlas Research Network 2013, 
Tyner, Tognon et al. 2018). This has demonstrated that the number of recurrent somatic variants in 
AML is very low (average 2 - 5) in comparison with the numbers reported from a variety of solid 
cancers. This has provided support for Gilliland and Griffin´s postulation that as few as two 
mutations can suffice for AML initiation (Welch, Ley et al. 2012, Cancer Genome Atlas Research 
Network 2013).  
Identification of recurring mutational patterns in AML involving FLT3-LMs and mutations or 
structural rearrangements categorised as class 2 mutations has further strengthened the hypothesis. 
This indicates that mutated FLT3 gene-products synergise with other variant gene products such 
as NPM1 and DNMT3A or with fusions such as PML-RARA in leukaemogenesis (Renneville, 
Roumier et al. 2008, Welch, Ley et al. 2012, Dovey, Cooper et al. 2017). Experimental studies 
have further confirmed this model. While FLT3-LMs in murine bone marrow transplantation 
assays as well as in knock in mice only result in myeloproliferative phenotypes (Kelly, Liu et al. 
2002, Li, Piloto et al. 2008) leukaemic disease development can be induced by coupling FLT3-
LMs with other recurrent genetic aberrations like inv(16) (Kim, Kojima et al. 2008), RUNX1-
RUNX1T1 (Schessl, Rawat et al. 2005), PML-RARA (Kelly, Kutok et al. 2002), NPM1 mutations 
(Mupo, Celani et al. 2013, Dovey, Cooper et al. 2017) or TET2 mutations (Shih, Jiang et al. 2015). 
Together this suggests that FLT3-LMs in isolation are insufficient to initiate leukaemia and that 
coupling with specific additional genetic aberration is necessary and sufficient for disease 
transformation in these models. 
Tumour evolution is a further characteristic of AML disease trajectories9. This has been recognised 
since the 1980s when changes in cytogenetic characteristics were observed by longitudinal 
karyotype evaluation at disease presentation and at disease recurrence. Both increasing complexity 
as well as loss of cytogenetic aberrancies were observed through individual disease courses 
                                               
9 In the Beat AML sample cohort (Tyner, Tognon et al. 2018), studied in paper II, 608 samples from 519 individuals 
were exome-sequenced. A total of 58 individuals were serially sampled, 44 twice, 12 three times and 2 individuals 
four times. As a reference regarding the pattern of tumour evolution I provide a supplemental clinical table and a 





(Garson, Hagemeijer et al. 1989, Kern, Haferlach et al. 2002). By studying temporal molecular 
patterns of recurrently mutated genes in AML two discrete evolutionary pathways have been 
suggested: i) persistence of the leukaemic founder clone followed by mutation gain and disease 
recurrence and ii) progression of minor sub-clones following a branched evolutionary pattern 
(Ding, Ley et al. 2012, Hirsch, Zhang et al. 2016).  
Changes in FLT3-LM pattern are frequent during AML disease advancement, and emergence of 
FLT3-LMs in myelodysplastic syndrome is associated with progression to AML (Horiike, Yokota 
et al. 1997). Relapse in FLT3-LM patients is recurrently characterised by loss of the wild type allele 
though copy neutral loss of heterozygosity (Thiede, Steudel et al. 2002, Stirewalt, Pogosova-
Agadjanyan et al. 2014, Loke, Akiki et al. 2015). Gain or loss of FLT3-LMs upon disease re-
presentation is also not uncommon, and shifts from one to an alternative FLT3-LM variant has been 
described (Nakano, Kiyoi et al. 1999, Hovland, Gjertsen et al. 2002, Kottaridis, Gale et al. 2002, 
Shih, Huang et al. 2002, Schnittger, Schoch et al. 2004, Tiesmeier, Muller-Tidow et al. 2004, 
Warren, Luthra et al. 2012, Wakita, Yamaguchi et al. 2013, Garg, Nagata et al. 2015). The 
relationship between FLT3-LM alleles and FLT3 wild type alleles has additionally been shown to 
correlate with disease outcome, where both loss of the wild type allele (Whitman, Archer et al. 
2001) as well as predomination of the FLT3-LM allele is associated with inferior outcome (Thiede, 
Steudel et al. 2002, Gale, Green et al. 2008). Similar patterns have been described for other somatic 
variants in AML (Hirsch, Zhang et al. 2016). Although less frequent than in FLT3-LM AML, 
NPM1 mutation status has been demonstrated to be changeable through disease courses. This was 
first reported in 2014 when Webersinke et al. reported an AML case study describing a shift in 
NPM1 variant between diagnosis and disease recurrence (Webersinke, Kranewitter et al. 2014), 
and has later been validated to be a recurring finding in larger cohorts, where approximately 9-10% 
of NPM1 positive AML cases were described as NPM1 wild-type at time of disease recurrence 
(Hollein, Meggendorfer et al. 2018, Cocciardi, Dolnik et al. 2019). 
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Most multicellular organisms develop from a unicellular origin and gradually expand to the size of 
up to several trillions of individual cells. An average human body is approximated to comprise 
around 3.72 x 1013 cells (Bianconi, Piovesan et al. 2013), all characterised by approximately the 
same DNA sequence. Despite this there are up to several hundred morphologically distinct cell 
types in a typical metazoan body, including the human (Valentine, Collins et al. 1994). This is the 
result of cell diversification though differentiation. Through epigenetic remodelling, expression of 
distinct combinations of genes and through post-translational modification of gene products cells 




Halbritter et al. 2016, Liu, Beyer et al. 2016). These mechanisms not only direct human ontogeny 
but are crucial in the orientation of adult tissue homeostasis, composed and maintained of cells 
with varying differential potential and self-renewal capabilities (Biteau, Hochmuth et al. 2011).  
Despite mutations occurring in all somatic cells, the ability of a single cell to evolve through 
somatic evolution is restrained by the replicable properties of the cell. Most propagating human 
cells are short lived and eventually terminally differentiate and exhaust. This fact suggested the 
hypothesis of somatic stem cells as the cellular origin of cancer development (Cairns 1975), as well 
as the concept of stem cell restriction: the number of stem cells and stem cell divisions ultimately 
confine somatic evolution by natural selection and the probability of complex adaptations (Germain 
2012). Recently, tissue specific stem cell division quantification estimates have been demonstrated 
to correlate with cancer incidence corroborating this hypothesis (Tomasetti and Vogelstein 2015). 
While the traditional focus of somatic mutation theory has been on germline variants and somatic 
mutations caused by exposure to mutagens Tomasetti and colleagues postulate that random errors 
related to DNA replication in stem cells largely explain tissue specific cancer incidence irrespective 
of environmental conditions (Tomasetti, Li et al. 2017). 
In the haematopoietic tissue functional heterogeneity has predominantly been explored by 
expanding haematopoietic cells in vitro and in animal models. It has through such experimental 
approaches been established that not all haematopoietic cells form colonies and not all 
haematopoietic cells engraft or can sustain engraftment in immunodeficient mice (Bruce and Van 
Der Gaag 1963). This has led to a model of the haematopoietic system as an interdependent 
hierarchy of differentiation processes. The discrete cellular components are related to each other 
through lines of descent where the cells express discrete properties and functions, including 
proliferative capabilities and life spans. At the top of the hierarchy the long-lived haematopoietic 
stem cells reside. These cells are not yet lineage restricted and can provide progeny that can 
differentiate to any haematopoietic cell type. Descending down the hierarchy lineage commitment 
increases, and the potential fates of individual cells are gradually restricted while more specialised 
functional traits are expressed. Haematopoietic stem cells are currently operationally defined as 
cells capable of reconstituting the entire blood system, coupling self-renewal capacity as well as 
multi-lineage differential potential. A unifying descriptive delineation of haematopoietic stem cells 
has been challenging to establish, and the validity of various proposals combining cellular surface 
proteins as markers remain controversial (Pinho and Frenette 2019).  
For a haematopoietic cell to become a source of leukaemia it needs to couple two fundamental and 
naturally opposing properties: immortalisation and proliferation. As an explanation for this it has 
been suggested that the orderly organisation of the haematopoietic system is somewhat retained in 




leukaemia. This claim has been experimentally supported by work presented by John Dick and his 
associates on AML xenograft models. The first AML engraftment was reported by Lapidot in John 
Dick´s group in 1994 (Lapidot, Sirard et al. 1994), and in 1997 Bonnet and Dick demonstrated the 
hierarchical organisation of AML, characterised by cell populations of varying self-renewal 
capacity (Bonnet and Dick 1997). In analogy with the delineation of normal haematopoietic stem 
cells leukaemic stem cells are functionally defined by their ability to serially initiate and maintain 
leukaemia in immunocompromised xenograft models (Hope, Jin et al. 2004, Lane and Gilliland 
2010).  
The clinical importance of leukaemic stem cells is supported by relationships between high 
expression of genes associated with leukaemic stem cells and adverse outcome in AML (Gentles, 
Plevritis et al. 2010, Eppert, Takenaka et al. 2011). Leukaemic stem cell theory emphasises 
functional multiplicity within the leukaemic cell compartment. Recently the molecular resolution 
of intra-leukaemic heterogeneity has been increased by the application of next generation 
sequencing approaches. This has demonstrated that leukaemic samples are characterised by 
epigenetic and transcriptional diversity, defined as contribution of multiple haematopoietic 
regulatory programs simultaneously. Single cell profiling has revealed that this diversity derives 
from two principal sources: i) cells characterised by non-conventional transcriptional states as well 
as ii) inter-cellular heterogeneity across differentiation spaces (Levine, Simonds et al. 2015, 
Corces, Buenrostro et al. 2016, van Galen, Hovestadt et al. 2019). Advances in cell-sort technology 
and improvement in knowledge of cell-identity markers has further enabled the identification and 
functional characterisation of pre-leukaemic stem-cells within AML specimens, characterised by 
some, but not all genetic variants present in the corresponding bulk leukaemic sample, as well as 
the ability to provide multilineage progeny in functional assays (Jan, Snyder et al. 2012, Shlush, 
Zandi et al. 2014). 
Despite FLT3 being first discovered and described as a haematopoietic stem cell marker 
(Matthews, Jordan et al. 1991, Small, Levenstein et al. 1994), the literature exploring FLT3-LM 
AML within the conceptual framing for cancer stem cell theory is less elaborated that the body of 
knowledge of FLT3 and somatic mutation theory and tumour evolution theory. Samples derived 
from FLT3-LM individuals have been shown to engraft readily in immunocompromised mice, 
suggesting that at least some FLT3-LM AML cells possess leukaemic stem cell properties 
(Rombouts, Blokland et al. 2000). Levis and colleagues further validated this observation by 
comparing the FLT3-LM allele distribution in primary stem cell enriched and bulk samples 
demonstrating that FLT3-LMs were present within the leukaemic stem-cell compartment (Levis, 
Murphy et al. 2005). The study of FLT3-LM knock in mice has demonstrated numerical as well as 




of FLT3-LM expression as well as functional impact, characterised by haematopoietic stem cell 
depletion as well as impaired transplant capabilities (Chu, Heiser et al. 2012). Other investigators 
have reassessed the importance of FLT3 mediated haematopoietic regulation, demonstrating that 
both FLT3 as well as FLT3-ligand are dispensable in the maintenance of murine haematopoiesis, 
as well as in posttransplant haematopoietic expansion (Buza-Vidas, Cheng et al. 2009). Expression 
of FLT3 on long-term haematopoietic stem cells has further been questioned based on functional 
exploration of various haematopoietic stem cells populations as well as lineage tracing 
experiments. Both suggest that FLT3 transcription is associated with the transition to multi-potent 
progenitor cells and loss of self-renewal capacity (Adolfsson, Borge et al. 2001, Boyer, Beaudin et 
al. 2012). This claim was recently substantiated by single cell RNA experiments, identifying a 
strong negative correlation between gene expression of haematopoietic stem cell related genes and 
FLT3 mRNA transcripts (Mead, Neo et al. 2017). Functionally it has further been shown that live 
cells within the blast compartment of FLT3-LM mutated AML samples are functionally diverse 
and characterised by heterogenous activation of STAT3 and STAT5 following in vitro stimulation 
with granulocyte colony stimulating factor (Irish, Hovland et al. 2004). Together this line of 
findings suggests that the impact of FLT3-LMs may vary substantially across phenotypically 
diverse cells within single leukaemic cell compartments. 
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In addition to somatic mutation theory, tumour evolution theory and cancer stem cell theory I 
identified a number of publications exploring alternative explanatory models. A handful of 
publications focused on the preleukaemic stages of AML, presenting compelling evidence of AML 
as a progression of somatic evolution. Epigenetic contributions in the development of AML were 
explored in a substantial number of papers, and a few reports investigated the relationship between 





According to evolutionary theory biodiversification is a necessary feature of sustained life in a 
dynamically changing environment. As mutations can result in altered gene products, both in 
qualitative and quantitative terms, changes in DNA is a primary source for divergence, expanding 
the possibility of transcriptional states and corresponding cellular properties. Although genetic 
recombination is the prevailing source of biodiversification in most metazoans, DNA integrity is 
continuously broken, resulting in postzygotic somatic diversification (Loewe and Hill 2010, 
Forsberg, Gisselsson et al. 2017, Risques and Kennedy 2018). Somatic evolution and somatic cells 




maintenance of the integrity of the organism. Cancer can in this model be understood in terms of 
the conflict between evolutionary processes in two dimensions: i) the evolutionary force favouring 
cohesion of the individual and ii) the evolutionary trajectories of single cells, continuously 
diversifying and exploring novel trails (Cairns 1975, Merlo, Pepper et al. 2006). Cancer would in 
this view occur when the second dimension overrides the first. 
Mutations are defined as persistent changes in the DNA sequence and results from errors in DNA 
replication or DNA damage followed by low fidelity repair. Mutations are frequently assumed to 
be stochastic and agnostic, meaning that the occurrence of a mutation is independent of its 
translational consequences (Hershberg 2015). Mutations are, however, bio-mechanistic and bio-
chemical events and mutation patterns are thus non-random, reflecting specific underlying causes 
of DNA damage and/or impaired repair mechanisms (Loewe and Hill 2010, Alexandrov, Nik-
Zainal et al. 2013, Alexandrov, Ju et al. 2016). The distribution of cancer related somatic mutations 
has been described as asymmetrical, which has been attributed to patterns of DNA replication 
timing as well higher order genomic organisation and epigenetic configurations (Woo and Li 2012, 
Liu, De et al. 2013, Polak, Karlic et al. 2015).  
AML has an abrupt clinical presentation and until recently little was known about the dynamics of 
leukaemogenesis leading up to disease eruption. Exploration of large biobanks of healthy blood 
cells by capture based deep next generation sequencing methods has resulted in identification of 
early stages of leukaemogenesis that previously have been unobserved. These studies have 
demonstrated that acquisition of somatic genetic variants, including mutations in leukaemia 
associated genes like DNMT3A, ASXL1 and TET2, are common events in normal haematopoietic 
stem and progenitor cells. Such cells have additionally been shown to frequently expand 
disproportionally with age, resulting in clonal haematopoiesis, which is associated with an 
increased risk of presenting with a haematological malignancy as well as all-cause mortality 
(Genovese, Kahler et al. 2014, Xie, Lu et al. 2014, Young, Challen et al. 2016, Acuna-Hidalgo, 
Sengul et al. 2017, Zink, Stacey et al. 2017, Desai, Mencia-Trinchant et al. 2018). Similar 
observations have been made across various tissue types, including the oesophagus, the 
endometrium, and the skin, where mutations in certain cancer related genes have been 
demonstrated to be prevalent and persisting, including NOTCH1, NRAS, KRAS, PIK3CA and TP53 
(Martincorena, Roshan et al. 2015, Martincorena, Fowler et al. 2018, Risques and Kennedy 2018, 




healthy haematopoietic stem cells and leukaemic cells is comparable and correlate strongly with 
chronological age (Welch, Ley et al. 2012, Lo Sardo, Ferguson et al. 2017). Estimations based on 
the quantification of somatic variants in healthy haematopoietic stem cells suggest that each year 
throughout life approximately 10 new somatic variants sequentially accumulate in every 
haematopoietic stem cell, of which only a small fraction are located in protein coding regions. The 
yearly incidence rate of exonic mutations is estimated to be as low as 0.13 +/- 0.02 per 
haematopoietic stem cell (Welch, Ley et al. 2012). This suggests that mutations accumulate over 
time, and that most somatic variants are not causally involved in leukaemogenesis. Even 
distribution of variants across different regions of the genome (e.g. protein coding sequence, 
regulatory sequence and non-regulatory sequence) and a recurring mutational pattern 
characterising both healthy as well as AML exomes, (both dominated by C>T/A>G transitions, 
probably resulting from deamination of methylcytosine residues leading to subsequent transitions) 
further support random accumulation of somatic variants as a function of time (Welch, Ley et al. 
2012) (Figure 9).  
Continuous acquisition and persistence of mutations suggest that metazoans are characterised by 
increasing genomic complexity as a function of time. An analogous pattern of gradual genomic 
diversification is increasingly recognised as a part of cancer development. Metaphase karyotyping 
has revealed cytogenetic diversity in 15-20% of AML cases (Bochtler, Stolzel et al. 2013, Baron, 
Stevens-Kroef et al. 2018). Inferred cell population size by variant allele fraction patterns of 
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0.069–0.858 exonic mutations per year
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samples analysed by bulk next generations sequencing assays has suggested that intra-leukaemic 
genomic heterogeneity is common (Welch, Ley et al. 2012, Cancer Genome Atlas Research 
Network 2013). Single cell sequencing techniques have shed light on the profoundness of genomic 
diversity and confirmed that bulk AML samples frequently consist of numerous genotypically 
diverse cell populations (Paguirigan, Smith et al. 2015, Potter, Miraki-Moud et al. 2018, van Galen, 
Hovestadt et al. 2019). Engraftment studies have further supported clonal complexity by 
demonstration of genetic variation within the leukaemic stem cell compartment (Klco, Spencer et 
al. 2014, Vick, Rothenberg et al. 2015, Shlush, Mitchell et al. 2017, Wang, Sanchez-Martin et al. 
2017). Such heterogeneity is well described in FLT3-LM AML where FLT3-LMs frequently 
characterise only a minor fraction of cells in leukaemic specimens, and not infrequently multiple 
FLT3-LMs are identified (Horiike, Yokota et al. 1997, Kottaridis, Gale et al. 2001, Gale, Green et 
al. 2008, Meshinchi, Stirewalt et al. 2008, Borthakur, Kantarjian et al. 2012, Schranz, Hubmann et 
al. 2018, Blatte, Schmalbrock et al. 2019). Moreover, treatment with FLT3 inhibitors is 
characterised by rapid emergence of non-FLT3-LM cell populations characterised by mutations in 
alternate signalling genes, including NRAS, PTPN11 and CBL, suggesting that AML is a 





Cell fate disruption has long been recognised as a core feature of AML. Block in terminal 
differentiation is a characteristic feature of leukaemic cells, and lineage-specific transcription 
factors are recurrently mutated or involved in structural rearrangements (Tenen 2003). The 
identification of several recurrently mutated genes coding for critical epigenetic regulators, 
including DNA methylation-related genes, chromatin modifiers as well as cohesin-complex genes 
(Cancer Genome Atlas Research Network 2013), led to increased attention to epigenetic 
dysregulation as a contributor of leukaemogenesis. However, the explanatory power of epigenetic 
contributions in oncogenesis exceeds the translational effects of mutated genes. Epigenetics is a 
collective term referring to molecular features that i) contribute in the instruction of gene 
expression and ii) are vertically passed down to cellular progeny through mitotic and meiotic 
inheritance, much like the transfer of information through DNA replication (Berger, Kouzarides et 
al. 2009, Cavalli and Heard 2019). This has led to the postulation that epigenetic “hits” are 
complementary causal contributions in leukaemogenesis analogous to the acquisition of somatic 
variants (Figure 10). Based on the study of DNA methylation patterns in myelodysplastic 
syndromes and AML, with a particular focus on disease progression, Jiang and colleagues suggest 
that aberrant DNA methylation is a prevailing mechanism for tumour suppressor silencing, 




Epigenetic contribution in leukaemogenesis is supported by observations from the study of FLT3-
LM AML. FLT3-LMs frequently co-occur with mutations in genes involved in epigenetic 
regulation, including DNMT3A and TET2 (Cancer Genome Atlas Research Network 2013, Garg, 
Nagata et al. 2015, Tyner, Tognon et al. 2018). DNMT3A is proposed to behave as a tumour 
suppressor in haematopoietic cells, and loss of DNMT3A expression is associated with 
enhancement of haematopoietic stem self-renewal and impaired differentiation through 
hypomethylation of important regulatory enhancer regions. When combined with FLT3-LMs acute 
leukaemia rapidly manifests in animal models (Yang, Rodriguez et al. 2016). In a mouse model 
FLT3-LMs in combination with a TET2 loss of function mutation resulted in epigenetic silencing 
of GATA2, an event suggested to be involved in leukaemic transformation (Shih, Jiang et al. 2015). 
Similarly, epigenetic deregulation of GATA1 has been proposed to be involved in leukaemic 
transformation in NPM1 and FLT3-LM AML (Sportoletti, Celani et al. 2019). Regulatory RNA 
has also been implicated in leukaemogenesis. An example is MicroRNA 155 that has been shown 
to be up-regulated in FLT3-LM AML (Garzon, Garofalo et al. 2008, Whitman, Maharry et al. 
2010). Experimentally it has been shown than induction of MicroRNA 155 is a down-stream 
signalling effect of FLT3, which ultimately results in dysregulation of the myeloid transcription 
factor PU.1 (Gerloff, Grundler et al. 2014). Comparing FLT3-LM positive and negative primary 
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leukaemic samples Cauchy and colleagues further identified a chromatin signature specifically 
associated with FLT3-LM signalling, shaped by activation of STAT and MAPK pathways resulting 









Somatic mutations may result in phenotypic change upon translation, and occasionally the 
phenotypic change has an effect on cellular fitness. Several publications presented data that 
underscored the importance of gene-context as a variable that influences the value of somatic 
variants. These findings suggest that identical mutations and subsequent gene products may confer 
variable qualities dependent on individual context and connectivity (Schaefer and Serrano 2016). 
FLT3-LMs display remarkable tissue and cell-of-origin specificity. Expansion of cells with somatic 
changes in the FLT3 gene have almost exclusively been described in cancers originating from cell-
subsets known to express FLT3 (Yokota, Kiyoi et al. 1997, Serve, Flesch et al. 1999). This suggest 
that the oncogenic effect of FLT3-LMs is restricted to features of the transcriptome: a FLT3-LM 
appears to provide a significant change in cellular fitness only when transcribed. The relationship 
between FLT3-LMs and cell ontogeny and cell identity has been experimentally substantiated. By 
comparing the effect of FLT3-LMs in adult and foetal murine haematopoietic progenitor cells 
Porter and colleagues demonstrated that the ability of FLT3-LMs to induce self-renewal as well as 
myeloid commitment programs in part was dependent on the preceding transcriptional state of the 
cell (Porter, Cluster et al. 2016), suggesting that the size and direction of fitness change introduced 
by FLT3-LMs is context dependent.  
Identification of some but not all leukaemia associated mutations in otherwise healthy individuals 
(Genovese, Kahler et al. 2014, Xie, Lu et al. 2014, Young, Challen et al. 2016, Acuna-Hidalgo, 
Sengul et al. 2017, Zink, Stacey et al. 2017, Desai, Mencia-Trinchant et al. 2018), as well as 
persistence of the same mutations post induction therapy and in enduring remissions (Hirsch, Tang 
et al. 2017, Jongen-Lavrencic, Grob et al. 2018) suggest that the sequential order of mutation 
acquisition influence cellular phenotype and the probability of successive expansion. Recurring 
variant allele patterns suggest that FLT3-LMs are acquired late in the leukaemogenic process, as 
they almost always co-exist with somatic variants with higher variant allele frequencies (Malkin 
2011). This interpretation has been supported by single cell sequencing studies demonstrating that 
FLT3-LMs frequently characterise only a subset of leukaemic cell populations (Shouval, Shlush et 
al. 2014, Potter, Miraki-Moud et al. 2018). Experimentally it has been demonstrated that when 
FLT3-LMs are introduced in “healthy” haematopoietic stem cells the ability of self-renewal is 
disrupted, resulting in depletion of the haematopoietic stem cells pool (Chu, Heiser et al. 2012). 




phenotype result in synthetic lethality (Oveland, Wergeland et al. 2012). This is further supported 
by the context dependent prognostic association related to FLT3-LMs, influenced by co-occurrence 
of mutations in alternate genes (Papaemmanuil, Gerstung et al. 2016). In sum this implies that the 
preceding genotype may influence the translational effects of somatic variants. 
These principles are not restricted to FLT3-LM AML. In myeloproliferative neoplasms it has been 
demonstrated that the order of which genes are mutated influence both cellular characteristics, as 
well as clinical features and response to targeted therapy (Ortmann, Kent et al. 2015). The cell of 
origin influences the oncogenic effects of MLL-rearrangements in AML (Krivtsov, Figueroa et al. 
2013). Chao and colleagues have further elaborated on this principle. They were able to de-
differentiate primary MLL-rearranged AML blasts to induced pluripotent stem cells and re-
differentiate the cells into various non-haematopoietic cell-types, all presenting normal 
phenotypes. When cell-identity was redirected towards haematopoietic destinations leukaemic 
properties re-emerged (Chao, Gentles et al. 2017). Analogously a much older experiment 
demonstrated that transduction of a leukaemogenic MLL fusion gene in haematopoietic progenitor 
cells of various differentiation stages recurrently resulted in maturation arrest at the same 
differentiation level (Cozzio, Passegue et al. 2003). Observations from germline variants and 
hereditary cancer predisposition syndromes provide theoretical support. It is well recognised that 
germline genetic variants frequently result in composite phenotypes, suggesting substantial 
molecular variability upon gene-product variant integration in various gene-environments. 
Furthermore, cancer penetrance is variable and frequently tissue specific. Li-Fraumeni syndrome, 
characterised by TP53 germline variants, is known to increased risk of leukaemic presentation 
(Malkin 2011). The lifetime risk of leukaemia is, however, far from comparable to the reported 
transformation rate in somatically TP53 mutated clonal haematopoiesis where a 100% 
transformation rate recently was reported by Desai et al. (Desai, Mencia-Trinchant et al. 2018). 
Conversely, in myeloproliferative neoplasms is has been shown that TP53 mutated subpopulations 
of cells are frequently present but only occasionally expand or transform to AML (Kubesova, 









The literature selected for the dissertation synthesis also included studies that suggest that the 
relevant gene-environment exceeds the limits of individual cells. This perspective was represented 
primarily through reports related to cell- and immunotherapy, but also comprised a handful of 
papers presenting evidence of context dependency with regards to therapeutic responses, as well 
as reports of evolutionary trajectories influenced by externally enforced selection pressure (Smith, 




It is estimated that the daily haematopoietic output of terminally differentiated haematopoietic cells 
approximates the magnitude of 5 x1011. The yield has been theorised to have a 10-20 folds 
expansive potential under conditions of demand (Creutzig, Zimmermann et al. 2016, Bolouri, 
Farrar et al. 2018). Maintenance of homeostatic conditions requires relentless production and 
expansion of cells from the top of the hierarchy to replenish the cells that have expired or been lost. 
Establishment of individual cell identity within the hierarchy is a co-produced process involving 
environmental cues (Zhu, Adli et al. 2013). The balance is sustained and stabilised through multiple 
systemic mechanisms, including circadian (Golan, Kumari et al. 2018), metabolic (Agathocleous, 
Meacham et al. 2017), endocrine (Abdelbaset-Ismail, Suszynska et al. 2016), immunological 
(Baldridge, King et al. 2010) and inflammatory pathways (Wilson, Laurenti et al. 2008). Cell 
extrinsic signals are internalised and transformed to altered cell behaviour through intra-cellular 
signalling pathways that ultimately result in the activation or inactivation of transcription factors 
responsible for the regulation of gene expression. Recent reports further suggest that activation of 
intra-cellular signalling pathways directly modify chromatin structure and histone configuration 
through post-translational modifications, directly contributing in epigenetic remodelling (Cavalli 
and Heard 2019). What follows is that similar environments result in phenotypic convergence 
across multiple cellular entities with a similar genetic and epigenetic configuration (Stadhouders, 
Filion et al. 2019). In line with this haematopoietic stem cells located at different organ sites differ 
with respect to differentiation trajectories and properties (Benz, Copley et al. 2012). Functional 
differences among haematopoietic stem cells in the same niche have been attributed to variation in 
precise location and relation to cellular and non-cellular niche components, like osteoblast, vascular 
cells and the stroma (Ghobrial, Detappe et al. 2018).  
The emphasis of microenvironmental and systemic contributions with regards to cell-identity adds 
to the theories of tumour evolution theory that cellular competition, adaptation and selection occurs 
in an adaptive and dynamically changing cell extrinsic environment. Evidence suggests that such 
variation is relevant with regards to leukaemic cell properties. It has been shown that culture 
conditions influence anti-leukaemic responses to a variety of therapeutic compounds (Karjalainen, 
Pemovska et al. 2017). FLT3-LM cells have been demonstrated to be less sensitive to direct FLT3 
inhibition when grown in culture media supplemented with FLT3-ligand, cytokines normally 
produced in the bone marrow, or when grown in co-culture with bone marrow derived stromal cells 
(Sato, Yang et al. 2011, Yang, Sexauer et al. 2014, Sung, Sugita et al. 2019). This suggest that 
leukaemic cells retain a certain level of connectivity and responsiveness with regards to their 
surroundings, resulting in cell-extrinsic environment dependency with regards to gene variant 




Changes in gene environment occasionally result in emergence of cell populations with shared 
genetic or phenotypic features. Emergence of clonal haematopoiesis following medical cancer 
treatment is not uncommon (Coombs, Zehir et al. 2017). Wong and colleagues showed that discrete 
therapeutic strategies resulted in expansion of genetically defined cellular subsets, characterised by 
DNA damage response genes following chemotherapy and DNMT3A mutations succeeding 
haematopoietic stem cell transplantation, respectively (Wong, Miller et al. 2018). Molecular 
characteristics of treatment related AML similarly reflect preceding therapy. Del(5q) and/or partial 
or complete deletion of chromosome 7, TP53 mutations and chromosome 17 alterations are 
associated with previous exposure to alkylating agents. Similarly, MLL- or RUNX1- 
rearrangements are linked to preceding topoisomerase II inhibitor treatment (McNerney, Godley 
et al. 2017). Furthermore, the choice of anticancer treatment appears to have an effect on 
subsequent molecular disease progression patterns. Disease recurrence following chemotherapy 
has been shown to converge towards a more stem-cell-like state, as defined by genome-wide DNA 
methylation profiling (Triche Jr, Johnson et al. 2018). Post-transplant disease re-presentation has 
analogously been characterised by deregulation of gene expression in a pattern hypothesised to 
promote immune escape from T-cell mediated allorecognition (Christopher, Petti et al. 2018).  
In FLT3-LM AML treatment failure of FLT3 directed tyrosine kinase inhibitors after initial 
response is characterised by emergence of up to several novel FLT3 mutations conferring resistance 
(Man, Fung et al. 2012, Smith, Wang et al. 2012, Baker, Zimmerman et al. 2013, Smith, Paguirigan 
et al. 2017), or as previously mentioned cell populations characterised by alternate mutations in 
signalling genes (McMahon, Ferng et al. 2019, Zhang, Savage et al. 2019). Analogously IDH1 and 
IDH2 isoform switching has been observed in relation to IDH-targeted therapy (Harding, Lowery 
et al. 2018, Intlekofer, Shih et al. 2018).  
Converging evolution is further a feature described in relation to cancer cell migration and 
metastasis, where cancer-cells from various primary sites typically converge upon establishment 
in the same distant organ location (Cunningham, Brown et al. 2015). This illustrates the orientating 
potency of environmental conditions and suggests that endogen variation in gene-environments 
may influence disease trajectories.  
The observations presented above suggest that variation in mutational profiles in part can be 
accounted for by variation in individual cell heritage as well as supra-cellular gene environments. 
Of particular interest with regards to the relevance of such mechanisms are patterns of phenotypic 
and molecular convergence within cancers: plurality of mutations in the same gene or genes with 
similar functions, that occur independently in various cells at various sites and at various time 
points within the same tumour. This observation is frequently attributed to Gerlinger and colleagues 




carcinomas (Gerlinger, Rowan et al. 2012). Numerical variation of FLT3-LM alleles within single 
individuals is as previously mentioned, however, a recurrent finding in the AML research literature, 
first described already in 1997, and later repeatedly reproduced (Horiike, Yokota et al. 1997, 
Kottaridis, Gale et al. 2001, Gale, Green et al. 2008, Meshinchi, Stirewalt et al. 2008, Borthakur, 
Kantarjian et al. 2012, Schranz, Hubmann et al. 2018, Blatte, Schmalbrock et al. 2019). Convergent 
phenotypic and molecular evolution is also observed in other subgroups of AML. Jang et al. 
identified more than one cKIT mutation in 30 of 69 cKIT positive core-binding factor leukaemia 
specimens (Jang, Yoon et al. 2016), and plurality of cKIT mutations have been described to either 
co-occur in the same cell or to define discrete cell populations (Tan, Liu et al. 2018). Similarly, 
Itzykson and colleagues described clonal interference between cell populations defined by discrete 
signalling drivers in 28% of core-binding factor leukaemia (Itzykson, Duployez et al. 2018). 
Likewise, dual IDH1 and IDH2 mutations have recently been described in AML (Platt, Fathi et al. 
2015).  
Convergent molecular evolution has also been shown across other cancers, including BTG1 
deletions in acute lymphoblastic leukaemia (Waanders, Scheijen et al. 2012), plural BRAF and 
KRAS mutations in chronic lymphocytic leukaemia (Vendramini, Bomben et al. 2019), BRAF 
mutations in malignant melanoma (Valachis and Ullenhag 2017), CTNNB1 mutations in 
hepatocellular carcinoma (Friemel, Rechsteiner et al. 2015), CIC, FUBP1 and NOTCH1 mutations 
in gliomas (Suzuki, Aoki et al. 2015), PTEN, TP53 variants as well as deletion of coding exons of 
RUNX1 and amplification of FGFR2 in breast cancer (Yates, Gerstung et al. 2015), and KRAS and 
EGFR mutations in lung cancer (Kalikaki, Koutsopoulos et al. 2008, Marchetti, Milella et al. 2009). 
Even combinations of mutations have been described to evolve in parallel, like the combination 
TP53 and ATRX mutations in a patient with glioma (Suzuki, Aoki et al. 2015). Convergent 
molecular evolution has also been described in premalignant lesions like intra-ductal papillary 




The extension of gene-context to consider cell-extrinsic gene-relationships proposes that supra-
cellular processes and events influence the onset and transitions related to leukaemogenesis 
(Ghobrial, Detappe et al. 2018). This is supported by evidence of leukaemic development in animal 
models characterised by bone progenitor cell dysfunction (Raaijmakers, Mukherjee et al. 2010) 




mechanisms have been implied in human leukaemogenesis in relation to germline variants and 
their contribution in the development of myeloid malignancies10 (Dong, Yu et al. 2016).
The immune system is another systemic dimension attributed importance with regards to 
leukaemia. Allogeneic stem cell therapy is an important treatment modality in high risk AML 
(Knorr, Goldberg et al. 2019). Comparison of variable graft composition have demonstrated a 
correlation between the fraction of mature immune cell subsets and relapse rates, suggesting an 
immune mediated graft versus leukaemia effect (Horowitz, Gale et al. 1990) and a relationship 
between immunocompetency and leukaemia.  
These results in part align with the conceptual framework of tissue organisation field theory 
presented by Sonnenschein and Soto in 2000 (Figure 11). This theory emerged in response to what 
                                               
10 PTPN11 activating mutations, characterizing approximately 50% of patients with Noonan syndrome, are associated 
with increased risk presentation with a myeloproliferative neoplasm. Mechanistically disease progression has been 
shown to involve excessive production of the chemokine CCL3 by bone marrow mesenchymal cells (Dong, Yu et al. 
2016). 
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Sonnenschein and Soto interpreted as conceptual inconsistences related to the basic premises of 
somatic mutation theory. They questioned the assumption of quiescent as the default mode of 
somatic cells, and argued that expansion is a more fundamental feature, in line with the behaviour 
of unicellular organisms as well as embryonic stem cells. They further argued that cancer results 
from the breakdown of biological organisation, hence proposing that cancer is an emergent 
phenomenon that cannot be explained at a cellular level (Sonnenschein and Soto 2000).  
To my knowledge the tissue organisation field theory is not clearly articulated in the FLT3-LM 
AML literature. There are, however, numerous findings that corroborate relationships between 
features of the cell-extrinsic environment and the relative distribution of FLT3-LMs in AML. 
Positive FLT3-LM status has repeatedly been associated with patient features like younger age and 
female gender (Schnittger, Schoch et al. 2002, Blau, Berenstein et al. 2013). According to somatic 
mutation theory the age-related incidence increase of AML can be accounted for by acquisition 
and accumulation of mutations as rate limiting events with regards to disease eruption. This model 
does, however, not account for discrete age-related differences with regards to specifically mutated 
genes, as has recently been described not only for FLT3 but also multiple other gene variants 
(Creutzig, Zimmermann et al. 2016, Bolouri, Farrar et al. 2018). While the male excess of AML 
has been attributed to sex-related variation in exposure to mutagens (Cartwright, Gurney et al. 
2002), this does not fully account for a female majority among individuals with FLT3-LM AML. 
Recent lines of evidence emphasise age-related changes in the bone marrow tissue composition. 
Increasing age is associated with gradual corrosion of haematopoietic cohesion resulting in 
dysregulation of haematopoietic stem cells (Lee, Jeong et al. 2019, Verovskaya, Dellorusso et al. 
2019). Sex further shape intra-cellular, micro-environmental and systemic gene-context with 
temporal variation. In an age dependent manner puberty (Hero, Wickman et al. 2005, Peng, Yu et 
al. 2018), sex steroid cyclicity (Chaireti, Lindahl et al. 2016, Kempe, Eklund et al. 2018), pregnancy 
(Nakada, Oguro et al. 2014, Aghaeepour, Ganio et al. 2017) and menopause (Heo, Chen et al. 2015) 
all influence haematopoietic and immune regulation as well as stromal bone marrow conditions, 
including the functional properties of bone marrow derived mesenchymal stromal cells (Siegel, 





In this section, I have reviewed the research literature on AML (or more precisely, a selection of 
highly cited research papers studying AML) and discussed it in terms of how it expresses, or lends, 
support to the various theoretical frameworks for cancer, including somatic mutation theory, 
tumour evolution theory and cancer stem cell theory. I have also presented and discussed various 
findings that appear to go beyond these three frameworks and pointed to a variety of 
complementary models. So far in the discussion, we may conclude that AML is not only a highly 
heterogenous and dynamic phenomenon but also one that only with difficulty can be accounted for 
by a single explanatory model. In particular, somatic mutation theory alone is not sufficient to 
explain the diversity of empirical findings. Indeed, the observations and experimental results 
presented in this section appear to support explanatory models in which individual cell trajectories 
are profoundly relational and where phenotypes of course are constrained by genotype but, to the 
extent that they become persistent, also lend themselves to explanation in terms of their external 



























Precise management of AML 
Assessment of the literature selection with regards to precision medicine related approaches 
revealed that the majority of papers explicitly articulated a potential future clinical relevance with 
regards to their findings. Based on current definitions of precision medicine (Yates, Seoane et al. 
2018) close to all applications proposed were precision medicine related. A synthesis of the 
objectives suggests that a major goal in haemato-oncology is to improve disease specific outcome 
through a collection of molecular oriented approaches, comprising i) identification of precise 
disease boundaries, ii) delineation of biologically diverse cases into molecular homogenous disease 
subgroups, iii) development of molecular tools applicable for risk-adapted clinical management, 
and iv) identification and exploration of novel druggable molecular targets (Figure 13). In the 
following I summarise the strategies identified in the literature selection, and I explore how they 
relate to the theories of leukaemia presented in the previous chapter (Figure 14). 
Disease delineation 
While identification of certain chromosomal rearrangements 11  is sufficient to confirm AML 
diagnosis irrespective of blast percentage (Vardiman, Harris et al. 2002, Vardiman, Thiele et al. 
2009, Arber, Orazi et al. 2016) most AML cases are diagnosed in accordance with an arbitrary 
morphological cut-off based on enumeration of blasts in a bone marrow smear (Arber, Orazi et al. 
                                               
11 Identification of t(8;21)(q22;q22), inv(16)(p13q22), t(16;16)(p13;q22) or t(15;17)(q22;q12) is sufficient for AML 
diagnosis, irrespective of blast counts. 
Figure 13: Precision haemato-oncology aims at improving disease management and outcome by i) identification of molecular 
defined disease boundaries, ii) determination of molecular delineations between disease subgroups, iii) development of molecular 





2016). The validity of the current cytogenetic boundaries are moreover dubious as these 
rearrangements are frequently found in the blood of otherwise healthy individuals at low 
frequencies (Janz, Potter et al. 2003, Song, Mercer et al. 2011), as well as in long term remissions 
(Miyamoto, Nagafuji et al. 1996, Tobal and Liu Yin 1998). This suggests that these borders are 
only useful and valid when paired with signs of bone marrow disease involvement. In the literature 
focusing on expanding the knowledge base with regards to tumour evolution a recurrent argument 
identified was that sharper diagnostic boundaries could facilitate improved clinical management of 
AML. More precise disease boundaries could aid earlier disease detection as well as improved 
disease monitoring and therapy response assessment (Walter, Shen et al. 2012, Corces-
Zimmerman, Hong et al. 2014, Genovese, Kahler et al. 2014, Shlush, Zandi et al. 2014). The 
distribution of causal narratives in the AML literature suggested that acquisition and accumulation 
of somatic mutations are understood as the prevailing causal contributors and rate limiting events 
in AML pathogenesis. According to somatic mutation theory molecular boundaries (e.g. mutations 
or epigenetic hits) separating non-leukaemia and leukaemia do exist. In line with this I found that 
identification of molecular features causally related to leukaemic transformation and disease 
progression is a key precision oncology related goal.  
)		
The last decades have been characterised by substantial shifts in the boundaries and sub-categories 
of AML, resulting in gradual stratification of the disease (Harris, Jaffe et al. 2000, Vardiman, Thiele 
et al. 2009, Arber, Orazi et al. 2016). The current World Health Organisation (WHO) classification 
framework for myeloid neoplasms and acute leukaemia (Supplementary table 2) comprises 
cytogenetic, molecular genetics, cytomorphology, germline variant associated, and aetiology 
founded sub-groups (Arber, Orazi et al. 2016). According to somatic mutation theory and tumour 
evolution theory the extensive molecular heterogeneity of AML is suggestive of plural molecular 
causal chains leading to disease eruption. In accordance with this interpretation I found that 
delineation of subgroups with shared molecular pathophysiology is an important aspiration in 
precision haemato-oncology. In relation to a proposed purely genomic classification system of 
AML the authors argued: “Cancer develops from somatically acquired driver mutations, which 
account for the myriad biologic and clinical complexities of the disease. A classification of cancers 
that is based on causality is likely to be durable, reproducible, and clinically relevant” 
(Papaemmanuil, Gerstung et al. 2016), underscoring the relevance of somatic mutation theory in 





The importance of more precise delineation and increased sub-stratification of AML is motivated 
by aspirations of improving disease specific outcome. Due to the aggressive nature of AML 
improvements in therapeutic strategies are considered instrumental in achieving such progress 
(Dohner, Estey et al. 2017). In AML treatment considerations are influenced by factors like 
availability of treatment, affordability, patient preferences and patient features like age, 
comorbidities and performance status. Increasingly, however, disease specific characteristics 
inform clinical decision making, including cytogenetic and molecular features (Cheson, Cassileth 
et al. 1990, Cheson, Bennett et al. 2003, Dohner, Estey et al. 2010, Dohner, Estey et al. 2017, 
O'Donnell, Tallman et al. 2017). Disease management plans are guided by assessment and 
balancing of risk related to probability of obtaining curation or disease control as opposed to the 
hazard of treatment induced morbidity and mortality (Dohner, Estey et al. 2017). Accordingly, risk 
classification systems are important clinical tools in the management of AML. Increasing number 
of strata characterise the development of such risk stratification systems over time (Cheson, 
Cassileth et al. 1990, Cheson, Bennett et al. 2003, Dohner, Estey et al. 2010, Dohner, Estey et al. 
2017, O'Donnell, Tallman et al. 2017). Knowledge generation with regards to risk assessment was 
strongly represented in the literature, suggesting that predictive refinement is considered an 
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stratification of newly diagnosed AML patients based on characterisation of a selection of 
cytogenetic and molecular genetic markers 12  and to adapt treatment plans accordingly 
(Supplementary table 3) (Dohner, Estey et al. 2017, O'Donnell, Tallman et al. 2017), the literature 
assessment demonstrated plurality of approaches. Expression of single genes, gene-expression 
profiles, epigenetic features and cell identity quantification were all shown to correlate with 
outcome in AML. Increasingly also longitudinal risk assessment is recommended. This is primarily 
obtained by response evaluation following induction therapy and further refines the treatment 
algorithm, informing post-remission strategies (Dohner, Estey et al. 2017). In sum this suggests 
that predictive practices are less stringently related to somatic mutation theory than disease 
delineation and sub-classification. 
	!	
Identification of novel treatment targets was the dominating precision medicine related approach 
identified in the literature selection. An appraisal of the targeting strategies suggested that efforts 
aimed at leveraging molecular pathways implicated in disease pathogenesis has dominated the drug 
development landscape in AML over the last 20 years. The majority of papers focused on inhibition 
of oncogenic effectors attributed to driver mutations (Ley, Mardis et al. 2008), including FLT3, 
IDH1 and IDH2 targeted strategies. Analogously, work focused on characterisation of epigenetic 
mechanisms proposed epigenetic targets or strategies (Jiang, Dunbar et al. 2009), while projects 
exploring the relationship between leukaemic cells and the microenvironment suggested 
therapeutic inhibition of leukaemic cell dependencies (Zeng, Shi et al. 2009). Authors exploring 
temporal disease dynamics offered various rationales for the superior benefit of targeting early 
(Corces-Zimmerman, Hong et al. 2014) or late (Smith, Wang et al. 2012) somatic variants, 
respectively. Work characterising various cells sub-sets related to treatment failure, including pre-
leukaemic cells and leukaemic stem cells, reasoned that identification and targeting of cell specific 
features would improve treatment outcomes (Jin, Hope et al. 2006, Somervaille and Cleary 2006, 
Majeti, Becker et al. 2009, Jan, Snyder et al. 2012, Corces-Zimmerman, Hong et al. 2014). In a 
subset of papers assumptions with regards to pathophysiology were challenging to identify. The 
majority of these papers focused on characterising leukaemic cell identity by exploring what made 
the leukaemic cells different from their non-leukaemic counter-parts. The majority of such papers 
inferred that these differences are potential therapeutic targets. 
                                               
12 Among the most impactful risk stratification systems is the European LeukemiaNet (ELN) recommendations, 
developed by an international expert panel, first published in 2010 and later revised in 2017. In North America the 





FLT3-LM AML is repeatedly portrayed as a classic case of somatic mutation theory and tumour 
evolution theory, where acquisition of FLT3-LMs represents the transition between non-leukaemia 
and leukaemia (Gilliland and Griffin 2002, Welch, Ley et al. 2012). FLT3-LMs are recurrent and 
as an important haematopoietic regulator altered FLT3 function is a plausible cause of altered cell 
behaviour. FLT3-LMs correlate with cell and disease phenotypes as well as with outcome. In cell 
and animal model systems expression of FLT3-LMs result in AML-like cell behaviour, which is 
suppressed by FLT3 inhibition, and in combination with specific gene variants FLT3-LMs are both 
necessary and sufficient to generate acute leukaemia in mice. Despite these lines of evidence 
acquisition of FLT3-LMs poorly delineates leukaemic transitions in AML patients. Despite the low 
abundancy of somatic variants in AML patterns of convergent molecular evolution in FLT3-LM 
AML is common and the pattern of FLT3-LM allele burden frequently suggest that FLT3-LM cells 
are sub-clonal. Within the frames of somatic mutation theory, it can be inferred that mutations not 
shared by all leukaemic cells at time of diagnosis are not necessary for AML eruption. Plurality of 
FLT3-LM at time of diagnosis conversely suggests that FLT3-LMs is in-sufficient for leukaemic 
transformation. 
FLT3-LM AML is frequently treated as a distinct biological entity in preclinical and clinical 
research as well as in clinical practice (Lagunas-Rangel and Chavez-Valencia 2017). Acquisition 
and loss of FLT3-LMs over the course of single leukaemic trajectories, however, makes them 
unsuitable both for disease delineation as well as sub-group classification. Accordingly, FLT3-LMs 
are not confined to a single disease category within the current WHO classification system, and are 
rather dispersed across most sub-categories, though with varying frequency.  
Positive FLT3-LM status correlates with poor outcome and is integrated in modern risk 
stratification guidelines leading to risk-adapted treatment decisions (Dohner, Estey et al. 2017, 
O'Donnell, Tallman et al. 2017). Context-dependency with regards to the predictive strength of 
FLT3-LMs, however, has made the optimal positioning of FLT3-LM status as a clinical decision-
making tool challenging. Initially FLT3-LM patients with recurrent cytogenetic abnormalities were 
categorised according to karyotype, while cytogenetic normal AML with positive FLT3-LM status 
was categorised as intermediate risk-I in a four-level risk classification system comprising 
favourable, intermediate-I, intermediate-II and adverse risk, respectively (Dohner, Estey et al. 
2010). In the 2017 update the number of risk groups was reduced to three: favourable, intermediate 
and adverse risk respectively. The risk impact attributed to FLT3-LMs in these guidelines is 
dependent not only on concurrent cytogenetic features but also NPM1 mutation status. In addition, 
the relative proportion of FLT3-LM alleles in the biospecimen (in relation to FLT3 wild type 




with NPM1 the prognosis is considered favourable as opposed to adverse-risk characterised by 
high FLT3-LM allelic ratio is combination with negative NPM1 mutation status.  
Despite two decades of preclinical and clinical trials focusing on FLT3 targeted treatment these 
efforts remained fruitless until very recently. Despite initial responses in some patients the clinical 
course is characterised by rapid emergence of resistant cell populations characterised by additional 
point mutations in FLT3 or mutations in unrelated genes (Man, Fung et al. 2012, Smith, Wang et 
al. 2012, Baker, Zimmerman et al. 2013, Smith, Paguirigan et al. 2017, McMahon, Ferng et al. 
2019, Zhang, Savage et al. 2019). The last few years several trials have, however, demonstrated 
some clinical benefit related to FLT3 inhibition in various settings in FLT3 mutated AML. This 
includes addition of a FLT3 inhibitor as maintenance therapy following standard induction therapy 
(Stone, Mandrekar et al. 2017) or bone marrow transplant (Burchert, Bug et al. 2018) as well as 
FLT3 inhibition as a single strategy in relapsed or refractory AML (Cortes, Khaled et al. 2019, 
Dhillon 2019). Currently ELN suggests that FLT3 mutated AML patients may be treated with 
midostaurin in addition to intensive chemotherapy (Dohner, Estey et al. 2017), while the National 
Comprehensive Cancer Network guidelines for AML (Version 3.2017) suggests that midostaurin 
is administered as consolidation treatment on day 8-21 after induction therapy with cytarabine and 
daunorubicin (O'Donnell, Tallman et al. 2017). Despite FLT3 treatment is currently included in 
treatment guidelines the added benefit is sobering. The RATIFY trial found that the 4-year over- 
all survival rate was 51.4% in FLT3 mutated patients treated with addition of midostaurin 
maintenance therapy as compared to 44.3% in the placebo group (Stone, Mandrekar et al. 2017). 
In the QuANTUM-R trial, comparing quizartinib with salvage chemotherapy in relapsed or 
refractory FLT3-LM AML, Cortes et al. recently observed a survival benefit in the quizartinib 
group, where median overall survival was 6.2 months compared with 4.7 months in the salvage 
chemotherapy group (Cortes, Khaled et al. 2019). In a similar trial gilteritinib treatment was shown 
to prolong survival in relapsed or refractory FLT3 mutated AML. The median overall survival was 
9.3 months in the gilteritinib treated patient group as opposed to 5.6 months in the group treated 
with salvage chemotherapy (Perl, Martinelli et al. 2019) 
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The literature review presented above has shown that a variety of explanatory models are 
represented in the AML literature, spanning all levels of biological organisation, ranging from 
genes to host extrinsic factors. The majority of explicit and implicit conceptual frameworks in the 
reviewed literature were characterised by strong directionality: the flow of information from genes 
to cell behaviour. The simplest version of these frameworks is somatic mutation theory, which 




assumption by including changes in heritable gene regulation patterns, and tumour evolution theory 
further develops the biological model by proposing that several mutations and/or epimutations are 
required for cellular transformation.  
The alignment of cancer stem cell theory with somatic mutation theory and its related models is 
slightly more complex. Cancer stem cell theory holds that the cell in which the mutations and 
epimutations occur and accumulate, possesses or acquires self-renewal properties and that such 
properties only characterise a fraction of the cells. What follows is that gene variants translate into 
phenotypic variation as a function of differentiation, complicating the linear flow of information 
from genotype to phenotype and, thus, challenging the categorical value of (epi)gene-variants. 
Explanatory models focusing on how the environment influences phenotype and genotype 
emergence further suggest that gene variants translate into variation as a function of individual 
dynamic connectivity. This perspective comes into conflict with the dominating model, reversing 
the direction of the causal chain. 
In the reviewed papers where both a causal narrative and one or several precision medicine related 
approaches were articulated, the clinical application frequently related directly to the causal 
narrative. Specifically, the majority of precision oncology related approaches identified were 
anchored to a gene-centred monocausal narrative. However, the case of FLT3-LM AML poses 
challenges related to somatic mutation theory and tumour evolution theory with regards to all 
identified precision oncology related approaches, including disease delineation, disease 
stratification, precise predictions as well as targeted therapy. In other words, there is a friction and 
a tension present in the case of FLT3-LM AML, between on one hand, what is known empirically 
about the phenomenon, and on the other, explicit and implicit theorisation as well as the in the 
choice of clinical approaches that are being devised. This discrepancy can be seen as the main 





In the preceding part of the introduction, I explored the relationship between precision oncology 
related approaches and conceptual frameworks in AML with focus on FLT3-LMs. This exploration 
concluded with a discrepancy between, on one hand, certain empirical features of FLT3-LM AML, 
and the theoretical and clinical approaches to the condition. The empirical work presented in this 
thesis represents a further exploration of the discrepancy. 
 
1. In paper I we expand on two independent observations from the FLT3-LM AML field that 
are poorly conceptually accounted for within the premises of somatic mutation theory: the 
sub-clonal as well as plural distribution of FLT3-LMs at time of diagnosis. We explore the 
relationship between FLT3 variant allele distribution and clinical characteristics, molecular 
features and outcome. 
 
2. In paper II we investigate and describe the relationship between sex and FLT3-LM status. 
 
3. In paper III we perform an in-depth interrogation of the disease course of a single FLT3-






This work is the synthesis of descriptive, experimental, and analytical practices. Full 
methodological accounts of the empirical work are presented in the method sections of the 
respective papers. This chapter focuses on more general methodological considerations and 
limitations. 
		
Paper I is a retrospective biomarker cohort study where relationships that frequently are attributed 
value in the delineation of AML sub-groups are assessed. A series of correlative analysis of 
biological and clinical variables, in addition to time to event analysis are performed. Therapeutic 
interventions influence disease trajectories and outcome in AML. Identified prognostic features 
within a study population consequently reflect population specific treatment practices. Over time 
identification of prognostic features has resulted in disease sub-stratification and non-random 
divergence of disease management. This means that when a biomarker is implemented in a 
treatment algorithm its “original biological signal” becomes in-assessable. It is, thus, unclear to 
what extent comparison between various AML strata in contemporary AML cohorts reflect 
variation in biology or variation in clinical care. FLT3-LMs have been accepted as negative 
prognostic markers for almost two decades, and FLT3-LM status is routinely implemented in 
clinical decision making. A recent publication demonstrated reduction of the prognostic impact of 
FLT3-LMs over time, implying relevant impact of risk-adapted practices (Badar, Kantarjian et al. 
2015). We are primarily interested in biological signals, an objective best explored in selected, 
uniformly treated and well characterised patient groups. We further focus on exploring differences 
within the FLT3-LM group, assuming they have been treated equally. We assess two independent 
and temporally separated cohorts, one representing a homogenous bio-bank cohort where FLT3-
LM status was retrospectively assigned, and one cohort more representative for contemporary 
practice, delineated by inclusion criteria of a clinical trial.  
In paper II we mostly explore publicly available datasets. Technological advances and novel 
organisational structures in research, including formation of large collaborative consortiums like 
the cancer genome atlas (TCGA) and more recently Beat AML, has allowed large cohorts of AML 
specimens to be analysed across multiple platforms (Cancer Genome Atlas Research Network 
2013, Tyner, Tognon et al. 2018) with raw and pre-processed data being provided for exploration 
by the research community at large. We mainly leverage these two datasets for a comparative 
analysis of female and male FLT3-LM AML patients. While the LAML-TCGA cohort is a highly 
selected sample population the Beat AML sample cohort represent a consecutive and unselected 




limited value with regards to time of event analysis. Exploration of the prognostic value of FLT3-
LM status was for this reason expanded to include the two cohorts analysed in paper I. 
Paper III is less conventional in structure and content as it presents an in-depth study of the disease 
trajectory of one single patient, performed with a suite of traditional as well as emerging precision 
medicine related practices. This includes molecular profiling as well as functional characterisation 
through drug sensitivity and resistance testing as well as repopulation assays. Knowledge generated 
by exploring a single case may have limited general value in the terms of its prospects for 
generalization. It does, however, offer the possibility of exploring and presenting biological 
complexity which might be invisible when averaging between individuals. 
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The three studies included in this dissertation involve characterisation of leukaemic biomaterial 
acquired from peripheral blood draws or bone marrow aspirates of AML patients. In paper I and II 
samples were collected at inclusion in study protocols or biobanks. In paper III serial sampling was 
performed and bio-banked in the context of clinical care. In contrast to the vast spatial 
heterogeneity in solid cancers there has been a general assumption that leukaemic cells are 
uniformly distributed amongst various bone marrow compartments and between the bone marrow 
and peripheral blood 13 . The leukaemic biomass, however, comprises genotypically and 
functionally diverse cell-populations questioning the validity of this assumption. Functional 
differences in composition of leukaemic cells derived from bone marrow and peripheral blood was 
noted already in the 1960s, and has lately been expanded on (Mauer and Fisher 1963, Weinkauff, 
Estey et al. 1999, Cheung, Chow et al. 2009, Sellar, Fraser et al. 2016, Wang, Sanchez-Martin et 
al. 2017). Recent observations suggest tissue relevant variability in genotype composition (Klco, 
Spencer et al. 2014, Ojamies, Kontro et al. 2018). Moreover, results from imaging studies using 
modalities like positron emission tomography have demonstrated uneven anatomical distribution 
of AML (Buck, Bommer et al. 2008, Vanderhoek, Juckett et al. 2011). The tissue origin in our 
studies is inconsistent, perhaps reflecting the inherent trade-offs related to clinical research. Bone 
marrow aspirates are associated with pain and risk of complications, while in some patients the 
number of circulating blasts is so low that peripheral blood draws are unsuitable due to low 
leukaemic content. For our purposes, however, Tong et al. have demonstrated complete 
concordance for detection of FLT3-LMs across paired peripheral blood and bone marrow samples, 
                                               
13 The Beat AML exome sequencing data set (Tyner, Tognon et al. 2018), studied in paper II, comprise a sample sub-
set of peripheral blood samples and bone marrow aspirates drawn on the same day (n=14). As a reference I provide 





as well as highly correlated allelic ratios (Tong, Sandhu et al. 2015). We did not observe any 
significant difference of numerical or allelic distribution in relation to sample origin (data not 
shown). Sample heterogeneity has further been shown to influence biomarker assessment 
(Pogosova-Agadjanyan, Moseley et al. 2018), and heterogeneous sample composition may result 
in non-random phenotypic and genotypic shifts by sample management procedures, including 
isolation, storage, thawing and expansion (Cantu, Dong et al. 2018). 
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The characterisation of FLT3-LM status in AML is routinely performed by polymerase chain 
reaction amplification, fragment analysis by capillary electrophoresis and Sanger sequencing. The 
polymerase chain reaction conditions influence the sensitivity of this analysis. The ratio between 
FLT3-LM and non-mutated patients in AML, thus, reflect assay sensitivity rather than the “true” 
naturally occurring distribution. While most articles discussing FLT3-LM AML state that the 
mutation occurs in approximately one third of AML patients, assessments by more sensitive 
methods have revealed that the proportion of FLT3-LM patients is substantially larger (Shouval, 
Shlush et al. 2014). When present at recurrence it has been demonstrated that it often is 
retrospectively detectable in the diagnostic sample when assessed with more sensitive assays 
(Ottone, Zaza et al. 2013, Zuffa, Franchini et al. 2015). Determination of the number of FLT3-LMs 
is also strongly influenced by technology, where more sensitive assays detect higher numbers of 
FLT3-LMs per patient (Schranz, Hubmann et al. 2018, Blatte, Schmalbrock et al. 2019). A recent 
report presented a novel bioinformatic pipeline annotating FLT3-LMs from deep next generation 
sequencing experiments. They reanalysed 28 FLT3-LM AML samples, previously characterised 
by conventional fragment analysis, and identified a total of 105 unique FLT3-LMs with a median 
of 3.8 LMs per sample. In comparison fragment analysis had only detected 34 LMs in the same 
sample set. Importantly, they analysed several samples from the same individuals at disease 
presentation, at remission and at disease recurrence and they demonstrated that LMs present in the 
diagnostic samples re-emerged at relapse despite mutation clearance at remission, suggesting 
persistence of mutated cells below the sensitivity threshold (Blatte, Schmalbrock et al. 2019). 
In paper I we explore the relationship between FLT3-LM distribution and molecular FLT3-LM 
features related to clinico-pathological characteristics as well as outcome. Based on the relationship 
between FLT3-LM and non-FLT3-LM alleles, estimated by fragment analysis by capillary 
electrophoresis, we made several assumptions related to FLT3-LM cell distribution. Based on 
sample availability the analysis was performed on complementary DNA rather than genomic DNA. 
We are hence measuring the relationship between various expressed FLT3 alleles rather than 




correlation between variant relationships in complementary and genomic DNA, suggesting that 
complementary DNA variant distribution largely reflects cell population composition. To our 
knowledge more than one discrete FLT3-LM has never been reported to co-occur within the same 
cell in AML. On the contrary, results from single cell sequencing studies indicate that different 
LMs represent discrete cellular subsets (Paguirigan, Smith et al. 2015). We accordingly assumed 
that plurality of FLT3-LMs represent plurality of cell populations that independently acquired 
FLT3-LMs. We further assumed that single FLT3-LM were restricted to one allele as long as the 
total variant distribution was below 50%. This may not be the case as loss of heterozygosity is well 
described in this locus in AML (Thiede, Steudel et al. 2002, Stirewalt, Pogosova-Agadjanyan et al. 
2014, Loke, Akiki et al. 2015), resulting in potential overestimation of the FLT3-LM cell fraction. 
In paper II and III we analyse and present results from next generation sequencing experiments. 
Whole-exome sequencing is a capture-based next generation sequencing method that is designed 
to cover the known protein coding part of genomic DNA. The aim is to produce high-quality, 
unbiased and interpretable data. The optimal conditions are achieved at uniformity of coverage and 
complete breadth (percentage of target bases that are sequenced a given number of times of the 
target bases). There are, however, several technical and biological challenges related to the method 
that tend to result in significant error rates. The source of errors can be related to sample 
representativeness, sample management and pre-processing, polymerase chain reaction errors 
through amplification, reference bias (capture probes that match the reference sequence and thus 
tend to preferentially enrich the reference allele at heterozygous sites), unmapped reads (low 
quality, sequencing errors, structural rearrangements, insertions in the query genome, deletions in 
the reference) and mis-mapped reads due to low complexity sequences. Increasing read length 
decreases the risk of mis-alignment. One major challenge is that GC-rich regions (CpG islands) are 
difficult to amplify as they remain annealed during amplification. These regions are hence prone 
to low coverage, which may result in gaps in the sequences and possibly false negatives. GC 
content variation also influences the hybridisation efficiency of sequence capture probes which 
may result in target regions that have little or no coverage. The confidence of variant whole-exome 
sequencing calls is in part based on discrimination between the sample of interest and a control. 
Application of whole-exome sequencing in search of postzygotic variants is consequently 
complicated by contamination of the control sample by leukaemic cells or cells from blood donors 
or bone marrow donors as well as the heterogeneity of the leukaemic sample. Coverage of the 
control sample is also an important feature as it influence statistical outcome (Sims, Sudbery et al. 
2014).  
Next generation sequencing is perhaps the technology that thus far has provided the strongest data 




diversity. The more composite the sample, the fewer mutations are called because of low frequency 
variants resulting in a strong bias towards detecting the most prevalent variants in a sample. High 
frequency of false positive and false negative calls makes it unreliable when attempting to assess 
rare cellular subsets (Sims, Sudbery et al. 2014). 
In paper III we perform both whole-exome sequencing as well as targeted sequencing on samples 
derived from patient derived xenograft models. Both methods are capture based and homologous 
sequences between murine and human DNA may lead to amplification of and alignment of residual 
murine DNA, resulting in false positive and false negative reads. For analysis of these whole-
exome sequencing experiments we therefor only considered calls that were detected at high 
confidence in the primary material. For the targeted sequencing we manually investigated the reads 
for mouse contamination. We found minor amplification of murine DNA in two of the targets 
resulting in both overestimation and underestimation of variant reads. The relative contribution of 
murine reads was, however, low and only marginally affecting variant allele frequencies.  
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In paper II we questioned whether there were any differentially expressed genes between female 
and male FLT3-LM positive samples in the Beat AML sample cohort. We did so by analysing the 
RNA sequencing data provided as part of the publication of the cohort (Tyner, Tognon et al. 2018). 
By conversion of RNA to complementary DNA followed by sequencing and read count 
quantification of transcripts one can address a variety of questions related to the transcriptome, 
within and between samples. The experimental and analytic pipeline of RNA sequencing resembles 
that of whole-exome sequencing and includes both in vitro as well as in silico procedures (Stark, 
Grzelak et al. 2019). Reading depth may vary between experiments. For comparison between 
samples read counts are normalised, like in Beat AML, to counts per million reads (CPM). This 
metric does not account for variation of counts per gene due to variation in gene length. One can, 
therefore, not compare expression between genes within the same sample. The comparative 
analysis performed included more than 20 000 statistical tests representing all identified protein 
coding genes. With an alpha set at 0.05 one would expect identification of more than 1000 hits by 
chance alone. We therefor adjusted for multiple testing effects and used a cut of false discovery 





In paper III we assess sample composition and relative distribution of various cell populations by 
means of two technological platforms: flow cytometry and mass cytometry respectively. Both flow 
and mass cytometry are antibody-based methods permitting synchronous characterisation of 
multiple molecular features at the resolution of single cells. Technically they differ with regards to 
labelling reagent as well as data acquisition technology. In flow cytometry experiments cells are 
stained with antibodies tagged with fluorophores, and fractions of cell populations corresponding 
to the relative strength of the fluorophore signal is quantified by means of the flow cytometer.  
Analogously, mass cytometry analysis is based on staining cells with antibodies tagged with rare-
earth metal isotopes of varying atomic mass. Relative quantification is subsequently acquired by 
an inductively-coupled plasma mass spectrometer (Fan, Wang et al. 2018). Our research objectives 
included i) delineation of non-leukaemic immune cells and leukaemic cells, ii) characterisation of 
immunophenotypic heterogeneity within the leukaemic cell compartment, iii) assessment of 
temporal variation in phenotype composition, iv) quantification of human cells in the patient 
derived xenograft models, and v) evaluation of environmental diversification by comparing 
leukaemic cells expanded in various organ sites and in discrete mice models. The different 
objectives required different resolution, which influenced the choice of platform. For phenotypic 
characterisation we used mass cytometry as it offers a multiplexing approach which is more robust 
than multi-colour flow cytometry. The analysis is based on a rationally selected panel of anti-bodies 
comprising canonical and non-canonical cell-surface markers resolving well known normal cell 
populations as well as the malignant cell compartment. For assessment of relative frequency of 
human cells in the patient-derived xenograft samples flow cytometry offered sufficient resolution. 
Both flow cytometry and mass cytometry are associated with technical noise. In mass cytometry 
contamination of ions from experimental conditions can generate channel specific noise. 
Analogously, several endogenous cell components produce autofluorescence and background 
signal at certain wavelengths. In flow cytometry the possibility of multiplexing is limited by wave 
length distributions of the light emitters. As the number of fluorophores is increased, resolution is 
limited by spectral overlap, spill-over and false positive signals in neighbouring channels. Mass 
cytometer sensitivity is isotope specific and signal intensity reflects panel composition. One can 
therefore only compare signal intensity within the same channel, further, complicated by signal 
spill-over. Ion instability can result in oxide formation resulting in the addition of 16 mass units. 
Furthermore, data processing of both flow and mass cytometry experiments tends to result in loss 
of information. Single cell high dimensional data are gated and analysed by various computational 
tools including clustering and dimensionality reduction algorithms. Despite a high level of 
automation several analytical steps comprise elements of subjectivity, including gating, 




final results (Olsen, Leipold et al. 2019). Of particular concern with regards to our analysis we 
analysed several samples comprising both human and murine cells. For mass cytometry analysis 
we analysed a stringent anti-human CD45 gate. Loss of CD45 low human cell subsets cannot be 




In paper II and III we present data from high throughput ex vivo functional drug screens. In paper 
II we analysed data from the Beat AML sample cohort (Tyner, Tognon et al. 2018) where they 
assayed live AML cells with a colorimetric MTS assay. In paper III we run a luminescent ATP 
assay (Pemovska, Kontro et al. 2013) on thawed vitally-preserved cells from the index patient as 
well as on cells derived from the patient derived xenograft models. Such viability assays are 
designed to test pharmacological dependencies of primary leukaemic cells under preselected 
conditions. Both selective drug sensitivity scores and area under the curve are measures of relative 
efficacy and express a function of the interaction of the primary leukaemic cells, the experimental 
conditions, and the assay specific read out. The experiments provide large amounts of data that can 
be used to characterise and compare various samples. Results may indicate sample specific 
variation in activity and dependency of molecular pathways. The preselected conditions, however, 
including growth conditions, incubation time, and choice of readout, may limit the utility of 
comparisons between drugs. The read-out of both the MTS and the ATP assay represent a proxy 
of cell proliferation and viability by estimation of metabolically active cells by quantification of 
NADH activity and ATP respectively (Gordon, Brown et al. 2018). The assays comprise 
compounds, however, that in a clinical context may be used in different ways, and they may provide 
clinical benefit through other mechanisms than inhibition of cellular proliferation. The assay 
further provides an average response across the cells in the sample and does not account for 
functional or genotypic heterogeneity within the specimens. An important example of the 
importance of this limitation was presented by Pratz and colleagues demonstrating that FLT3-ITD 
ratio correlated with in vitro responses to FLT3 targeted tyrosine kinase inhibitors (Pratz, Sato et 
al. 2010). A second objective related to this kind of high throughput platforms is to assess whether 
functional characterisation of primary patient material can guide therapy decisions and ultimately 
lead to improved outcomes, as indicated by Marinez-Cuadron and colleagues (Martinez-Cuadron, 





In paper III we explore gene gene-environment interactions and how various conditions influence 
leukaemic initiating potential in repopulation assays. The choice of mouse strain and model system 
has been shown to influence the pattern of engraftment of human material (Antonelli, Noort et al. 
2016, Wunderlich, Chou et al. 2018). We chose two variants of the NOD/SCID strain characterised 
by discrete features: i) a NOD/SCID line characterised by IL2RG knockout (NSG) and ii) a more 
humanised NOD/SCID line with IL2RG knockout in addition to transgenic expression of several 
human myeloid promoting cytokines, including SCF, GM-CSF and IL-3 (NSGS). We included 
both female and male animals. Leukaemic engraftment rate has been associated with observation 
time (Paczulla, Dirnhofer et al. 2017). We were predominantly interested in investigating disease 
initiation and propagation rather than engraftment and, thus, chose to sacrifice the mice at disease 
onset rather than a predefined timepoint. It has also been demonstrated that different clones 
distribute in an asymmetric fashion, varying between different skeleton location as well as between 
the skeleton and extra medullary sites (Belderbos, Koster et al. 2017). Due to scarcity of sample 
material such heterogeneity is unfortunately poorly accounted for in our analysis.  
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Statistics were performed in line with usual practice in the field. For pairwise comparison of 
normally distributed continuous variables we performed the Student´s t-test. The non-parametric 
Wilcoxon signed-rank test was applied for the pairwise comparison of continuous variables which 
failed to fulfill the requirements of a parametric test. For comparison of categorical variables, we 
performed 2x2 tables and applied the 2-sided Fisher exact test. Pearson correlation was used to test 
relationships between continuous variables. For time to event analysis overall survival was 
calculated by the Kaplan-Meier method and was visualised in Kaplan-Meier plots. The 2-sided log-
rank test was applied to compare Kaplan–Meier estimates. For continuous variables impact on 
outcome was evaluated by univariate cox models. For multivariate adjustment we performed 
multivariate Cox proportional hazards regression analysis. Statistical significance was considered 
to be indicated when the p-value was equal to or below a threshold of 0.05. Due to the multiple 
testing situation p-values were adjusted by the Benjamini-Hochberg method (Benjamini and 
Hochberg 1995) for differential gene expression analysis. Tests were performed in accordance with 
test specific requirements, and all the statistical calculations and the graphical representations were 
performed in R- Studio (version 1.1.453) and R (version 3.5.0). Graphs were made with ggplot2 





Through an appraisal of the conceptual frameworks presented in the AML research literature I have 
argued that theoretical premises are reflected in precision oncology related practices in AML, and 
that they predominantly rely on the premises of somatic mutation theory. Evidence supporting i) 
pervasiveness of somatic diversification, ii) patterns of converging molecular evolution, and iii) 
context dependency with regards to the qualities of specific gene variants in sum indicate limited 
explanatory potential with regards to this model. Expanding the FLT3-LM AML evidence base 
with regards to molecular convergence and context dependency I substantiate the relevance of these 
dimensions. Full accounts of the results are presented in the respective manuscripts. For a brief 
overview I refer to the abstracts. In concert they support a theory of leukaemia as a relational 
multidimensional process. In the following I shall discuss the evidence for this claim as well as its 
potential epistemic and translational implications. 
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While leukaemia is frequently described and categorised as an entity our results accentuate that 
FLT3-LM AML perhaps is best understood and described as an evolving process. In paper I we 
explored the distribution of FLT3-LMs in treatment naïve AML. We found that the fraction of the 
leukaemic disease that is characterised by FLT3-LMs is highly variable, ranging from a 
diminishing portion of the leukaemic cells to defining most of the tumour cell population. In paper 
III we show that the FLT3-LM allele fraction can be unstable over time. We further show that an 
individual leukaemic disease compartment can entail several FLT3-LM negative cell populations 
that can propagate leukaemia. We find that gene-environment correlate with the molecular 
manifestation of FLT3-LM AML as well as FLT3-LM cell properties. Of novelty we observe that 
relevant gene-context may include sex. 
FLT3-LM status is repeatedly found to predict outcome in intensively treated AML (Kiyoi, Naoe 
et al. 1999, Abu-Duhier, Goodeve et al. 2000, Kottaridis, Gale et al. 2001, Meshinchi, Woods et 
al. 2001, Frohling, Schlenk et al. 2002, Schlenk, Dohner et al. 2008, Patel, Gonen et al. 2012). 
Plurality or sub-clonality of FLT3-LMs at time of diagnosis as well as context dependency with 
regards to the translational consequences of FLT3-LMs suggests that the relationship between 
FLT3-LM status and disease outcome may be less linear than what is frequently proposed. 
Although most of the biomedical literature focuses on the direct translational effects of the FLT3-
LM protein alternative hypothesis are represented in the literature. While some authors have shown 
that FLT3-LMs are inducers of reactive oxygen species and genetic instability (Sallmyr, Fan et al. 
2008), others have suggested that FLT3-LMs are the result of such instability. FLT3-LMs have 




Towatari et al. 1998), and identification of plural FLT3-LMs early on led to the hypothesis “…that 
FLT3 aberrations are potentially not the causative event but the result of an inherent genetic 
instability of the leukaemic cells due to an as yet undefined defect” (Thiede, Steudel et al. 2002). 
It has later been suggested that FLT3-LMs may result from genetic instability induced by preceding 
mutations in genes coding for epigenetic modifiers (Wakita, Yamaguchi et al. 2013). Accumulating 
data comparing the load and composition of mutations in FLT3-LM AML and non-FLT3-LM 
AML, however, suggest that the number and pattern of somatic variants is similar (Garg, Nagata 
et al. 2015, Tyner, Tognon et al. 2018) reducing the probability of genetic instability as an 
important causal contributor.  
The different prognostic impact of FLT3-LMs and FLT3-TKD mutations, both resulting in 
constitutive activated kinase activity, has been a persistent conundrum in the AML literature 
(Mead, Linch et al. 2007). One explanation could be that the molecular mechanisms involved in 
LM formation confer prognostic impact, recently indicated by some authors (Borrow, Dyer et al. 
2019). While somatic ITDs rarely are reported in the literature the mechanism has been described 
in other genes in relation to malignancy. cKIT-ITDs are frequent findings in canine cutaneous mast 
cell tumours (Webster, Yuzbasiyan-Gurkan et al. 2006), and ITDs of the EGFR kinase domain 
characterise the majority of soft tissue tumours in infants (Wegert, Vokuhl et al. 2018). BCOR-
ITDs have been described in clear cell sarcoma of the kidney (Roy, Kumar et al. 2015), soft tissue 
undifferentiated round cell sarcoma of infancy (Kao, Sung et al. 2016), and in high-grade uterine 
sarcomas (Marino-Enriquez, Lauria et al. 2018). ITDs are bio-informatically challenging to 
identify in next generation sequencing data, suggesting that they are underreported. Novel analytic 
algorithms have facilitated ITD detection in such datasets. Rustagi et al. quantified the number of 
somatic ITDs in the LAML-TCGA cohort (Rustagi, Hampton et al. 2016), showing that ITDs are 
frequent somatic events across most AML cases. Analysing these data with respect to FLT3-LM 
























































status no correlation between the number of somatic ITDs and FLT3-LM status were found (Figure 
15), indicating that such a mechanism is unlikely. 
In the following section, based on observations from the empirical work presented in the three 
research papers included in this thesis and from a selection-centred perspective an alternative 
explanatory model that might account for the persisting relationship between FLT3-LM status and 




Convergent molecular evolution is a recurring observation in the empirical work of this thesis. The 
plurality of FLT3-LMs in AML as presented in paper I and the dual NRAS mutations characterising 
the index patient presented in paper III both illustrate intra-individual molecular convergence. 
Inter-individual convergence is exemplified by the sex-associated mutation patterns presented in 
paper II, and the recurrent engraftment of a rare molecular defined cell-population described in 
paper III.  
According to somatic mutation theory and tumour evolution theory AML is the result of acquisition 
of somatic variants followed by clonal selection. While the field has emphasised the impact of 
mutations as the source of selective benefit evolutionary theory suggests that convergence 
predominantly is the result of environmental constraints (Losos 2011). The arguments and results 
of this thesis question whether changes in selection pressure plays a more important role in 
leukaemogenesis than what is currently acknowledged in the research literature, as assessed in the 
literature review presented in the introduction. This claim is substantiated by recent observations 
from the study of treatment related AML. The onset of AML in individuals that have undergone 
genotoxic treatment has been considered strong supportive evidence of the importance of 
mutagenesis in AML pathogenesis. Recent reports, however, suggest that chemotherapy primarily 
promote leukaemogenesis through selection rather than by induction of mutations. Risk of 
developing treatment related AML is correlated to the presence of clonal haematopoiesis prior to 
initial chemotherapy (Gillis, Ball et al. 2017, Takahashi, Wang et al. 2017), and TP53 mutations 
have been reported to frequently be present 3-6 years prior to TP53 mutated AML presentation. In 
some cases, TP53 mutations have even been identified before administration of genotoxic therapy. 
Treatment related AML is further characterised by a similar mutation pattern as the one found in 
chemotherapy naïve patients, and the number of mutations does not exceed the number identified 
in de novo AML (Wong, Ramsingh et al. 2015). In light of this, one could speculate whether TP53 
mutations primarily provide a selective benefit in a setting where a TP53 response is induced, for 
example by chemotherapy (Anensen, Oyan et al. 2006, Oyan, Anensen et al. 2009). Similar 




includes a report describing the emergence of RAS-mutated leukaemia in a patient treated with a 
BRAF inhibitor for a malignant melanoma (Callahan, Rampal et al. 2012), and a paper presenting 
the manifestation of a FLT3-LM AML in relation to dis-continuation of sorafenib (tyrosine kinase 
inhibitor with FLT3 affinity) treatment for an unrelated papillary thyroid cancer (Kakiuchi, 
Yakushijin et al. 2018). The natural history of AML is reflected in mutational profiles (Lindsley, 
Mar et al. 2015). Similar observations have been made in solid cancers, linking gene mutation 
status with exposure. Distribution of driver mutations in lung cancer reflect historical smoking 
status (Mounawar, Mukeria et al. 2007), while the recurrent somatic variant pattern in liver cancer 
displaying biliary phenotype is associated with aetiology, differing between individuals with and 
without antecedent chronic hepatitis (Fujimoto, Furuta et al. 2015). Analogously, the mutation 
spectrum between sporadic and inflammatory bowel disease associated colorectal cancers has been 
shown to diverge (Robles, Traverso et al. 2016). In concert these observations suggest that 
genotype-emergence can be a function of gene-gene-environment interactions (Temko, Tomlinson 
et al. 2018). Thus, patterns of molecular convergence between individuals and within individuals 
could suggest prior or current shared ecological conditions. 
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In 1975 the embryologist Beatrice Mintz demonstrated reversal to non-malignancy of malignant 
mouse teratoma cells. Through integration into normal mouse blastocystes and subsequent orderly 
embryonic development the malignant cells integrated in the growing animal, resulting in a mosaic 
of healthy and normal functional tissue (Mintz and Illmensee 1975). This experiment is an elegant 
demonstration of how cell population trajectories are in part determined by environmental 
conditions. Traditionally cell identity has been understood as confined end-states of ordered 
unidirectional sequences of branching steps (Ferrell 2012). Cancer cells have consequently been 
considered designated actors. The emergence of genotypes as a result of cell extrinsic events or 
processes, however, challenge the categorical boundaries of cancer cells.  
Emergence of descriptive and experimental data has suggested a previously unrecognised degree 
of fluidity and plasticity among cell types (Nestorowa, Hamey et al. 2016, Karamitros, Stoilova et 
al. 2018). By transduction of four distinct transcription factors Takahashi and Yamanaka 
challenged the unidirectionality of cell fate trajectories, demonstrating that somatic human 
fibroblasts could be de-differentiated to pluripotency (Takahashi, Tanabe et al. 2007). Riddell and 
colleagues have similarly shown that this is possible within the haematopoietic system. Expression 
of six defined transcription factors was sufficient to induce haematopoietic stem cell properties in 
committed murine blood cells (Riddell, Gazit et al. 2014). Reversal of cell identify and gain of 




under certain conditions leukaemic cells characterised by loss of tumorigenic properties have been 
shown to require self-renewal properties (McKenzie, Ghisi et al. 2019). Based on this experimental 
evidence Laplane has presented a conceptual analysis suggesting that stemness as a cellular 
property may not be best represented by stem cells as confined entities, but rather as cells capable 
of stemness function (Laplane 2015). Founded on observations from our own work, in light of the 
evidence mentioned above and the conceptual analysis related to stem cells and stemness my claim 
is that it may not be unreasonable to think about cancer cells in similar terms, not as cellular entities 
but as cells capable of “cancer” or “neoplastic” function. 
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Results from next generation sequencing of bulk AML biomaterial has demonstrated that mutations 
in signalling genes usually are mutually exclusive, and that the majority of AML patients are 
characterised by only one mutation in such a gene (Cancer Genome Atlas Research Network 2013, 
Tyner, Tognon et al. 2018). Several studies, however, have demonstrated that at time of diagnosis 
AML frequently comprise multiple genetically discrete cell populations (Klco, Spencer et al. 2014, 
Shouval, Shlush et al. 2014, Paguirigan, Smith et al. 2015), indicating that bulk AML biomass 
assessment poorly captures the complexity of cell population composition. The multiplicity of 
FLT3-LMs in a substantial fraction of the FLT3-LM AML cases (Paper I), as well as the diversity 
of discrete genotypically defined cellular populations identified in the index patient (Paper III) 
underscores the relevance of this underestimation. Recurrent expansion of non-FLT3-LM cell 
populations harbouring mutations in other signalling genes following treatment with FLT3 
inhibitors further highlights that the index patient is representative, and that composite disease 
composition is clinically relevant (McMahon, Ferng et al. 2019, Zhang, Savage et al. 2019). The 
dominance of single genotypically defined cell populations, nevertheless, suggests uneven 
contribution of leukaemic propagation. In paper III we describe a patient derived cell population, 
characterised by a NRAS Q61L variant, that despite temporal persistence never became dominant 
in the patient from which it derived. Repeatedly, though, cells from this population engrafted and 
propagated leukaemia in the mouse models. This indicates that shifts in ecological conditions, 
either by changes in the composition of the leukaemic and pre-leukaemic biomass or as a direct 
consequence of the treatment, may alter the relative fitness of various genotypes. 
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The pattern of multiple FLT3-LMs in AML (Paper I) is strongly suggestive of intervals of latency 
where cells have acquired FLT3-LMs but do not express leukaemic properties. Perhaps the 




cancers in relation to treatment with non-genotoxic cancer agents, as the NRAS mutated and FLT3-
LM leukaemia described above, which both presented in relation to tyrosine kinase inhibition 
(Callahan, Rampal et al. 2012, Kakiuchi, Yakushijin et al. 2018) (Figure 16). Caution in 
interpreting these results are warranted as they represent single disease narratives, but the 
mechanism is not leukaemia specific and is supported by observation from other haeme-
malignancies and management of solid cancers. Expansion of B-cell clones and development of 
aggressive B-cell lymphoma in patients with myeloproliferative neoplasms treated with JAK1/2 
inhibitors have been reported (Porpaczy, Tripolt et al. 2018). It is not clear whether this can be 
attributed to the release of neoplastic properties as a direct effect of JAK1/2 inhibition, but it 
remains a possible explanation. Treatment with tyrosine kinase inhibitors like vemurafenib, a 
selective RAF inhibitor, is associated with emergence of RAS-mutated tumours unrelated to the 
primary cancers, including but not limited to squamous cell skin cancer (Boussemart, Routier et al. 
2013, Gibney, Messina et al. 2013). The specific mutational pattern suggests a direct mechanism 
where NRAS mutated cells with a malignant but constrained potential acquired a selective benefit 
as a consequence of RAF inhibition leading to emergence of neoplastic properties. 
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Although highly unusual, spontaneous AML remissions have been reported in the literature, 
including in FLT3-LM AML (Rashidi and Fisher 2015, Vachhani, Mendler et al. 2016). Whether 
such disease courses illustrate clearance of leukaemic cells or reversal of leukaemic properties is 
not known. Durable remissions followed by disease recurrence, however, are suggestive of long-
term persistence of cells with leukaemic potential. Although disease recurrence in AML usually 
occurs within a timeframe of 2 years relapse after durable disease-free intervals have been 
documented. Yilmaz and colleagues demonstrated that after a median latency of 7 years after initial 
remission 8 of 10 AML re-presentations were characterised by the initial founder mutation 
(Yilmaz, Wang et al. 2019). Farina and collegues presented a case report demonstrating 
longitudinal complex clonal dynamics following complete heamatological remission of AML. 
Through analysis of samples aquired over 22 years they described alternating expansion of various 
cytogenetically defined cell population without clinical signs of disease (Farina, Rossi et al. 2016). 
A recent case study described the presentation of a BCR-ABL1 mutant cell population presenting 
as a B-cell precursor acute lymphoblastic leukaemia in a young child. The leukaemia was 
successfully treated but 22 years later the patient developed AML, genetically characterised by the 
initial translocation (Ford, Mansur et al. 2015), demonstrating the time frame of which cells with 
leukaemic potential can persist without propagating disease. Donor cell leukaemia may further be 
accounted for in this model, where cells from a donor progress to re-initiate leukaemia in the 




technology has revealed that up to 5% of post-haematopoietic stem cell transplant relapses are 
attributable to expression of leukaemic properties in cells derived from the graft (Wiseman 2011).  
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Data from the study of chronic myeloid leukaemia and myeloproliferative neoplasms further 
support the relevance of gene-context dependency with regards to expression of neoplastic 
properties, both in relation to age and sex. Chronic myeloid leukaemia has frequently been 
attributed to the acquisition of the BCR-ABL fusion proteins, largely reliant on the relationship 
between expression of BCR-ABL and myeloproliferative phenotypes in animal models (Daley, Van 
Etten et al. 1990). BCR-ABL (p210) transcripts are, however, not infrequently expressed in healthy 
individuals (Ismail, Naffa et al. 2014), and while incidence of chronic myeloid leukaemia was 
substantially increased in Hiroshima A-bomb survivors, latency before disease onset was in the 
range of 10 to 40 years. Interestingly, the latency was three times longer in females compared to 
Cell populations defined by different genotypes
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males, corroborating the hypothesis of context dependency that includes sex-variation 
(Radivoyevitch, Jorgensen et al. 2019). Similar patterns are related to myeloproliferative 
neoplasms. While expression of JAK2 V617F result in myeloproliferative phenotypes in mice (Li, 
Spensberger et al. 2010) the same somatic variants have been described in the blood of healthy 
individuals (Acuna-Hidalgo, Sengul et al. 2017). Disease phenotype and mutational patterns also 
vary by age and sex (Spivak 2017).  
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Plurality of genetically discrete AML cell populations at time of diagnosis (Paper I/Paper III) can 
be accounted for within the paradigm of somatic mutation theory. AML can be considered a 
biphasic disease, characterised by a latency phase followed by a bone marrow failure phase, as 
proposed by Shlush and Mitchell (Shlush and Mitchell 2015). Based on the findings put forward 
in this thesis, however, I propose the alternative explanation that the transition from pre-leukaemia 
to leukaemia involves synchronous emergence of leukaemic properties in multiple cells. 
Based on the close relationship between precision medicine and the premises of somatic mutation 
theory I believe it is important to know if plurality of cell populations characterised by discrete 
“driver” mutations represent sub-clonal diversity or poly-clonality (Figure 17). Numerous driver 
mutations as an expression of sub-clonal diversity imply that discrete events occurred independent 
of each other after the leukaemia was initiated. Their contribution to single cell phenotypes is 
necessarily not required for the leukaemic property of single cells, but rather result in additional 
variation, perhaps influencing competitiveness throughout the disease course. In concert i) the rapid 
clinical onset of AML, ii) the limited number of somatic variants characterising the disease, and 
iii) observations suggesting relative stability of number of somatic variants across disease courses, 
suggest that if discrete driver mutations represent sub-clonal cell populations then AML is likely 
subclinical for a very long time prior to symptomatic presentation. The temporal resolution related 
to clonal heterogeneity and disease presentation is poorly understood. Welch and colleagues, 
however, observed that in patients with multiple sub-populations of cells within the leukaemic 
specimen the average number of mutations specific for what they defined as sub-clones was 40 
(range 6-110) as determined by whole-genome sequencing (Welch, Ley et al. 2012). Based on the 
estimated timeframe for which mutations accumulate this indicate that the sub-clones separated 
from the founder clone on average 4 years prior to disease presentation (range 6 months – 10 years). 
Under the assumption that i) mutated genes only translate to aberrant cell behaviour as a function 
of their relational connectivity and ii) that this network of relations is in constant motion, a mutated 
gene will only contribute in the expression of leukaemic properties under certain conditions. It is 




characterised by a gene-variant is destined for leukaemic propagation in the future. Only if this is 
possible a leukaemic latency phase can be considered “true” without expanding the category of 
AML to include individuals that would otherwise never progress to clinically relevant disease, 
perhaps even the entire population. The problem, however, is that there is no reliable way to 
forecast future fluctuations of gene-environments, either as forthcoming acquisition of novel 
somatic variants or systemic alterations such as immune or stress responses or exposure to chemical 
or pharmacological constraints (Laplane, Duluc et al. 2018).  
Conversely, plurality of driver mutations as an expression of poly-clonal disease presentation 
suggest that the mutations were not sufficient for the establishment of an AML disease phenotype. 
To my knowledge FLT3-LMs have never been described in clonal haematopoiesis or in healthy 
individuals. FLT3-LMs can, however, persist in the bone marrow at levels far below standard 
assays during remission (Blatte, Schmalbrock et al. 2019), suggesting that the fact that they are not 
detected does not imply that they are not there. It further signifies that an event at a higher level of 
organisation than single cells eventually resulted in emergence of leukaemic properties across 
discrete pre-leukaemic cell-subsets concurrently. This indicates that proximate cause of leukaemia 
may be distinctly different from acquisition of somatic mutations and that leukaemia may not 
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In light of this hypothesised trajectory it is not impossible that the prognostic impact of FLT3-LM 
status may be confounded by shared underlying features facilitating the emergence of FLT3-LMs. 
This could account for why high FLT3-LM variant distribution is a stronger predictor of poor 
outcome that for individuals characterised by single or plural FLT3-LMs as described in paper I. 
Notably, a similar observation has been made in core binding factor leukaemia, where expansion 
rather than detection of cKIT mutated cells predict poor overall survival (Allen, Hills et al. 2013). 
As with FLT3-LMs cKIT mutations in this context are frequently lost at relapse (Allen, Hills et al. 
2013), and higher sensitive assays have demonstrated that plural cKIT mutations at time of 
diagnosis is a recurrent finding (Jang, Yoon et al. 2016).  
We do not know which conditions that promote emergence of FLT3-LM mutated cells and 
simultaneously account for poor outcome. We may, however, speculate with basis in the biological 
understanding. FLT3 expressing haematopoietic progenitor cells are in part dependent on FLT3 
activation for expansion. One could hypothesise that a bone marrow environment chronically or 
transiently failing to sustain FLT3-ligand production, locally or systemically, could produce a 
selective benefit for FLT3-LM cells. An alternative explanation may be that FLT3-LM cells 
continuously explore leukaemia-like phenotypes. Emergence of such cells may, however, be 
supressed by a negative selective pressure imposed by the immune system which continuously 
suppress transcriptionally deviating cells. A progressive or transient deregulation of such an 
immune response could consequently results in abrupt expansion of several FLT3-LM cells 
synchronously. Such shared conditions or sequences of conditions could perhaps represent less 
arbitrary disease delineations. Both narratives involve loss of tissue adhesion as a function of 
changes in the tissue. Interestingly, strategies that target retained tissue dependencies are among 
the most successful medical approaches in oncology. This comprise oestrogen deprivation therapy 
by oestrogen antagonists or aromatase inhibitors in hormone receptor positive breast cancer 
(Harbeck and Gnant 2017) as well as androgen deprivation therapy in prostate cancer (Attard, 
Parker et al. 2016). This further account for the anti-leukaemic responses induced by FLT3 
inhibition in patients who are not FLT3 mutated (Knapper, Burnett et al. 2006, Fischer, Stone et 
al. 2010). 
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The central dogma in molecular biology is the unidirectional flow of information from genes to 
proteins; the “genotype-phenotype relationship” (Crick 1958). This bottom-up model has 
dominated the experimental work of biomedicine as well as the interpretation of observational data. 
Although the results and arguments put forward in this thesis in no way question the validity of 




the emphasis of understanding the “genotype-phenotype relationship” in linear unidirectional 
terms. To summarise my argument in general terms: metazoan cell identity, cell state and cell fate 
is determined by numerous intrinsic AND extrinsic factors. For any given cell the selection of 
potential cell identities and cell states is intrinsically defined by the cell’s genetic material, the 
DNA. Through quantitative or qualitative alterations of complex gene-interactions a somatic 
mutation can reshape the trajectories of cell fate. Through emergence of new molecular features 
mutations in the regulatory part of the DNA or mutated gene products can open up unconventional 
transcriptional states resulting in novel cellular properties. Cell identity and cell state is further 
strongly influenced by the cell´s line of descent, essentially defining the cells epigenetic 
configuration and confining the cells potential differentiation paths. Fundamentally metazoan cells 
are, however, neither self-sufficient nor self-governing. Metazoan cells are collective in nature, and 
every new cell develops into being profoundly embedded in context. Networks of cells co-produce 
and co-maintain tissue and organ integrity, and collectively perform plastic transformations in 
response to perturbations. Through interactions like physical contact, autocrine, paracrine and 
endocrine signals, the collective of cells co-operate through continuously modifying their 
individual epigenomes and transcriptomes, in response to their surroundings. (Bertolaso and Dieli 
2017). Under these premises, cancer, although frequently described as a “genetic” disease, more 
fundamentally is a manifestation of aberrant cell behaviour. Although mutations can change the 
boundary conditions for a cell’s repertoire of potential phenotypic expression the effect of a 
mutation on a cell is profoundly relational. As a cell or a line of descending cells phenotypically 
diversify by expressing non-canonical transcriptional states it is in part the conditions of the 
environment that defines if the change is beneficial or deleterious. The emergence of novel cellular 
properties can accordingly never be fully understood or accounted for at the cellular or sub-cellular 
level. The gene-environment provides a dynamic and relational substrate where the meaning of the 
gene variant is defined. As neoplastic properties emerge by force of gene-gene-environment 
alterations the most relevant question may not be how mutations arise and translate to change but 
how the gene gene-environment relationship restrict the potential translational effect of novel gene-
variants. Indeed, the nature of the “phenotype – emergent genotype relation” appears as a highly 
promising field to explore in cancer. Genotype emergence can under these premises be predictive 
of disease trajectories through association rather than through causation.  
From this argument certain implications would seem to follow for the expectations of current 





In AML accurate disease delineation is important as treatment decisions increasingly rely on 
biomarkers rather than clinical disease presentation. With increasing use of sequencing 
technologies in otherwise healthy individuals’ incidental findings of clonal haematopoiesis and 
pre-leukaemia are anticipated to rise. Leukaemic transitions seem, at least in some instances, to be 
multidimensional, challenging the validity of molecular defined disease delineation, as well as 
early and post-treatment detection of disease, as defined by molecular assays.  
The emergence of cell populations characterised by mutations in alternate signalling genes, as well 
as isoform switching under targeted therapy, suggest plasticity between the pre-leukaemic and 
leukaemic cell pool. The heterogeneity of the pre-leukaemic pool is not known. If the heterogeneity 
is extensive enough it could potentially challenge the validity of molecular sub-classification. The 
perspective of relationality further suggests potential arbitrariness with regards to current sub-
classification practises. AML disease stratification is strongly influenced by the ability to separate 
individuals into various risk groups based on cytogenetic and molecular genetic features (Arber, 
Orazi et al. 2016). Various subgroups of AML therefore largely reflect variation in response to the 
treatment combination of anthracyclines and cytarabine. It is not clear from a biological perspective 
how variation in specific treatment response reflects disease causality. Notably, several of the poor 
risk groups are associated with previous exposure to genotoxic treatment which potentially could 
account for their poor treatment outcome. In biological terms, one may hypothesise that these cells 
were already selected for by their ability of sustaining genotoxic stress without induction of 
apoptosis. It is not clear if genetic features would always be the best predictor of variation in 
treatment response. Subgroup analysis following a different treatment regimen would perhaps 
result in different separation. One could speculate whether drugs specifically targeting leukaemic 
stem cells or differentiation agents would lead to stronger predictive signals with regards to gene 
expression patterns or cytomorphology. Indeed, patients characterised by poor risk factors have 
been shown to respond comparably favourable to decitabine treatment (Welch, Petti et al. 2016).  
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Plurality of genotypically and phenotypically diverse cell populations characterised by discrete 
properties challenge the potential of molecular targeted therapy. Even if leukaemic transitions are 
poly-clonal several observations support a shared genetic ancestry in most cases (Ding, Ley et al. 
2012, Dvorakova, Racil et al. 2013, Jan and Majeti 2013, Hirsch, Zhang et al. 2016, Cocciardi, 
Dolnik et al. 2019). To what extent collective genetic identities represent therapeutic opportunities 
remains undetermined. The potential is supported by the benefit of all-trans-retinoic acid treatment 




the benefit of this strategy is, however, phenotypic heterogeneity as well as plasticity within a 
genotypically defined cell population. Variable expression and function of mutated gene products 
across the functional space of cancer cells may limit the efficacy of any molecular targeted strategy. 
As with FLT3-LMs, the variant expression or lack of expression on cells with self-renewal 
capabilities or potential for induction of self-renewal capabilities is non-trivial. If FLT3-LMs occur 
in leukaemic stem cells that do not express the gene and the impact of the mutation only presents 
as the cells progeny gradually differentiate then FLT3 targeted therapy will likely be of little utility 
in the eradication of the leukaemic stem cells. Analogously leukaemic stem cells in chronic 
myeloid leukaemia do not seem to depend on the BCR-ABL fusion proteins, perhaps accounting 
for why imatinib treatments does not cure chronic myeloid leukaemia (Hamilton, Helgason et al. 
2012).  
Targeted therapy confers a highly stringent constraint not only on target cancer cells but also all 
other cells expressing the target molecule. Since the properties of any cellular component are 
functions of its interactions it seems fair to assume that inhibition of any molecule will have 
context-specific consequences. Targeted therapy may therefore mediate clinical effects through 
mechanisms not considered when rationally developing the treatment, as well as result in 
unexpected toxicities and long-term consequences. In vitro tyrosine kinase inhibitor treatment of 
FLT3-LM cells is characterised by emergence of secondary mutations conferring therapy 
resistance. The mutational pattern has further been shown to differ in accordance with specific 
agents (von Bubnoff, Engh et al. 2009), and include mutations in other genes leading to activation 
of parallel signalling pathways, including NRAS variants (Piloto, Wright et al. 2007). The 
conceptualisation and categorisation of FLT3-LM as a distinct disease entity (in practical rather 
than formal terms), and the subsequent development and application of FLT3 targeted therapies 
have contributed in shaping novel AML disease trajectories characterised by the emergence of 
novel gene variants as well as unusual combinations of mutated genes, including the co-occurrence 
of FLT3-LMs and NRAS mutations (McMahon, Ferng et al. 2019, Zhang, Savage et al. 2019). One 
could imagine that changes in therapeutic practices could result in altered AML demographics 
where the composition of molecular characterised categories change reflecting novel constraints. 
While “the expectation is that progress in developing targeted therapies with reduced nonspecific 
cytotoxicity will result in a decrease in t-MN [therapy-related myeloid neoplasm] incidence” 
(McNerney, Godley et al. 2017), one could speculate whether targeted therapies confer an even 
stronger selective constraint on haematopoietic cells with an intrinsic but contained malignant 
potential, and that this potential could be unleashed through targeted treatment for unrelated 
conditions. Up to 16 different FLT3-LMs have been reported in single individuals at AML 
presentation and could indicate that FLT3-LM are frequent molecular events, that under “normal” 




off-target FLT3 inhibition as a result of broad tyrosine kinase inhibitors could result in expansion 
of FLT3 mutated bone marrow cells. While supported by the development of NRAS mutated 
neoplasm following BRAF inhibition a consistent increase in secondary malignancies in chronic 
myeloid leukaemia patients treated with imatinib has not been observed (Miranda, Lauseker et al. 
2016). Currently targeted therapies are predominantly administered in an end-of life setting. It will 
be important to monitor if the use of molecular targeted therapies up front, in adjuvant or 
consolidation treatment regiments, will result in emergence of neoplastic properties and novel 
forms of treatment related neoplasms. This is of particular importance considering therapeutic 
intervention in a preventive setting. 
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Risk assessment is a core approach in precision oncology. Successful risk-adapted therapy implies 
identification of risk followed by a mitigating intervention that improves the outcome of interest. 
This activity presupposes knowledge of the risk distribution as well as knowledge and availability 
of efficient interventions. The added benefit of this strategy can be asserted by comparing outcome 
in individuals that were treated in accordance with this strategy and those that were not. Such 
comparisons are preferably performed prospectively in randomised clinical trials, but such studies 
are often not performed. Risk-adapted management instead frequently rely on identification of risk 
followed by treatment modification where the added benefit is deduced by subgroup analysis or, 
in some cases remains hypothesised. 
In AML risk-adapted therapy based on cytogenetic and molecular profiling as well as therapeutic 
response assessment is recommended. The added benefit of many of these recommendations are, 
however, poorly validated and quantified (Rashidi, Walter et al. 2016, Dohner, Estey et al. 2017). 
The poor outcome associated with FLT3-LMs early on led to recommendations of allogeneic 
haematopoietic stem cell transplantation in first complete remission. Although observational 
studies suggest that this practice has result in improved outcomes prospective trials asserting the 
value of this intervention are missing (Dohner, Estey et al. 2010, Dohner, Estey et al. 2017). 
Analogously, despite lack of randomised clinical trial results demonstrating an added benefit of 
sorafenib in FLT3-LM AML (Serve, Krug et al. 2013) the drug has in some centres been 
administered in addition to standard chemotherapy in FLT3-LM patients since the beginning of the 
2000s. Recent retrospective observational reports suggest that this has provided benefit (Sasaki, 
Kantarjian et al. 2019, Yalniz, Abou Dalle et al. 2019), but the study designs cannot provide definite 
answers. Similarly, FLT3-targeted maintenance therapy in a post-transplant setting has been 
integrated in clinical care before randomised trials were performed. Retrospective assessment 




2016, Xuan, Wang et al. 2018, Battipaglia, Massoud et al. 2019), but solid conclusions cannot be 
drawn. Similarly, sorafenib treatment following relapse after allogeneic stem cell transplantation 
has been indicated to provide benefit as a salvage regimen (Xuan, Wang et al. 2019). While 
minimal residual disease assessment has received increased attention in the management of AML, 
evidence supporting the hypothesis that minimal residual disease informed clinical management 
significantly improve outcome in AML currently remain scares (Ommen 2016).  
Predictions of risk are by their nature probabilistic as they are inferred from evidence at a group 
level. Furthermore, the accuracy of risk estimates has to be evaluated at the group level, as the 
event rate for any given individual is either 1 or 0. Disease stratification results in smaller sample 
size. Over time entire sample populations change in line with evolving therapeutic landscapes. The 
influence treatment practices have on cell and disease trajectories suggest that one cannot transfer 
knowledge of predictive relationships across treatment regimens (Welch, Petti et al. 2016). As an 
example, an added benefit of sorafenib as post-transplant maintenance treatment may be standard-
induction-therapy specific. An induction-regimen comprising midostaurin maintenance, as is now 
frequently recommended in FLT3-LM AML, could lead to a residual cell fraction that does not 
respond to sorafenib. Similarly, as induction regimens diversify most likely so will the molecular 
composition of relapsed and refractory AML. It is not obvious that evidence of comparative 
effectiveness derived from this group will remain valid as the sample composition change in 
accordance with novel treatment strategies. Paradoxically precision medicine related approaches 
may result in decreased availability of knowledge that can inform clinical decision making, thus 
reducing the predictive precision with regards to benefits and hazards related to single 
interventions. 
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There is no sharp demarcation between precision and non-precision related medical approaches is 
challenging as precision oncology in many regards is a continuation of the reductionist biomedical 
traditions characterising medicine in the 20th and 21st century. As such, in the introduction I 
emphasised that the delineation of precision medicine is not best understood as evolution of 
practices, but rather as an expansion from medical practice to a techno-scientific imaginary. 
Although precision medicine has been presented as a societal endeavour, it is not the destination 
but rather a technical solution to a political oriented objective: namely to improve public health 
(Figure 18). Precision oncology is as such a means to this end and not a goal in and of its self. The 
question is therefore not if precision oncology is feasible, but if it is “feasible enough”, as to be 
both desirable, viable and sustainable within certain frames. This is a combined scientific, medical, 




intended and unintended consequences related to precision medicine far exceed the sum of 
measurable effects of single medical interventions. The hope, vision and objective of precision 
medicine shape research objectives, policy agendas (Horgan, Lawler et al. 2015), legal and 
regulatory frameworks, health care delivery systems and public expectations across the world 
(Tarkkala, Helén et al. 2019). 
In a well cited AML review paper Ferrara and Schiffer summarise the molecular knowledgebase 
with regards to AML pathophysiology and conclude: “Hopefully, this new biological information 
will contribute to less empirical approaches to treatment” (Ferrara and Schiffer 2013). This 
statement embodies seemingly prevailing thinking in the field. Precision medicine promotes a 
substantial change in the foundation of clinical decision making, characterised by increased 
reliance on bio-plausibility and de-evaluation of evidence. This is reflected in oncological practice. 
Stakeholders of precision oncology advocate increased pace in the translation and implementation 
of novel “promising” agents. This has resulted in deregulation and reduced evidence requirements 
for marked authorisation of novel drugs, including increased reliance on single arm studies as well 
as poorly validated surrogate endpoints (Chen, Raghunathan et al. 2019, Gyawali, Hey et al. 2019, 
Hilal, Sonbol et al. 2019, Zettler, Basch et al. 2019). Based on a systematic evaluation of cancer 
drugs approved by the European Medicines Agency in the period 2009-2013, Davies et al. 
demonstrate that the majority of novel oncological agents were approved with no clear evidence of 
clinical benefit and that evidence of clinically meaningful utility remained unfounded a minimum 
of 3 years after approval. Quantifiable benefits were marginal, and the estimated median life 
expansion provided when documented was only 2.7 months (Range:1 – 5.8 months) (Davis, Naci 
et al. 2017). Early marked-approval is further dis-incentivising for execution of confirmatory well 
powered randomised studies, resulting in absent quantification of comparative effectiveness. Lack 
of high level evidence further affect the possibility and validity of cost-benefit analysis 
(DeLoughery and Prasad 2018). Low-grade evidence paradoxically increase uncertainty in clinical 
decision making (Moscow, Fojo et al. 2018). Despite the failing empirical foundation (Djulbegovic 
and Ioannidis 2019) uptake of low-grade evidence in clinical care is substantial. There is an 
increase in use of off-label targeted therapy (Saiyed, Ong et al. 2017), despite evidence suggesting 
inefficiency (Le Tourneau, Delord et al. 2015). Some countries and health care delivery systems 
even have aliquoted funds for such practises, like the National Health Service (NHS, UK) Cancer 
Drug Funds. A recent analysis of the use of such solutions suggest no meaningful societal or patient 
value gain (Aggarwal, Fojo et al. 2017). 
These sobering results suggest that there is an increasing distance between the expectations and 
realisations of precision oncology. Repercussions of this friction are currently materialising across 




Casadevall 2015, MacLeod, Harris et al. 2016). The gradual implementation of low value precision 
oncology related strategies has contributed to a situation where the total financial burden of cancer 
treatment and cancer care is rapidly spiralling out of control (Aggarwal, Ginsburg et al. 2014). This 
has resulted in significant financial toxicity for cancer patients (Knight, Deal et al. 2018). In settings 
characterised by resource constraint this has further generated restrictions in the priority setting, 
which ultimately result in reduced availability of novel therapeutic agents within the frames of both 
public healthcare systems as well as from insurance providers. With these agents being available 
in the free market an increasing discrepancy in access to care is materialising. Individual cancer 
patients no longer only fight their disease, they also battle public institutions or insurers for access 
to treatment (Aggarwal, Ginsburg et al. 2014). Desperation, fear and increasing inequity may 
negatively influence phenomenological aspects of living and dying from cancer. Such experiences 
may further contribute in shaping public discourse, conceivably resulting in justified erosion of 
trust in scientific knowledge, medicine and policy makers. 
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This work has focused on a narrow selection of the AML literature as well as the knowledge base 
of FLT3-LM AML. By restricting the analysis in such a way, it is possible that I have captured 
only a limited range of assumptions and practices related to precision haemato-oncology. Despite 
these limitations I do believe that the considerations put forward in the discussion are relevant to 
other cancer related disciplines, as they refer to general reflections regarding the nature of cancer 
cells and how this relates to predominating theories of cancer as well as oncological knowledge 





The existence of limitations and disadvantages, in our case of somatic mutation theory and 
precision oncology, does not imply that they are without benefits. From a practitioner’s perspective 
the quality of a theory or a practice is not a direct function of its truth value but rather of its fitness 
for purpose (Funtowicz and Ravetz 1993). Experience has demonstrated that medical strategies 
based on somatic mutation theory are feasible, despite inherent biological limitations. Expansion 
of cell populations characterised by certain molecular markers may correlate with disease 
trajectories, and disease stratification and risk-adapted management as well as molecular targeted 
therapy does sometimes transform outcome in cancer subgroups. Combination regiments or 
sequential administration of drugs targeting various molecular pathways may ultimately improve 
response rates and temporally overcome resistance. Longitudinal disease monitoring and response 
assessment may further improve treatment algorithms, eventually resulting in improved outcome. 
Functional assessment like drug sensitivity and resistance testing or single cell signalling profiles 
may outperform molecular profiling as predictors of therapeutic response. In line with this 
reasoning what remains important is quantification of utility. I would argue that with regards to 
precision oncology utility must not only be demonstrated with regards to therapies but also in 
relation to methodology, and I would further argue that there is potential for strengthening the 
empirical evidence base with regards to the utility of current practices. 
The interpretation of FLT3-LM AML put forward in this thesis is intended to generate novel 
questions related to the biology of cancer and how it can be therapeutically exploited. In particular, 
I have wished to open up questions related to the relative contribution of somatic diversification, 
selection, adaptation and contingency in oncogenesis in general.  Resolution of these questions is 
not trivial and could inform the expectations in the present regarding the potential utility of both 
gene and cell centred screening and treatment monitoring approaches, in addition to the potential 
value of targeting specific molecular features. It could further inform the direction of research 
initiatives intended at reducing the risk of neoplastic progression. Limitations associated with the 
current gene and cell-centred paradigm further suggest that expanding perspectives may open up 
novel ways of conceptualising, categorising, and treating cancer that may advance the field. 
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This thesis has tried to explore an instance of the relationship between disease theory and precision 
medicine, in the highly specialised case of FLT3-LM AML. The current politico-medical discourse 
of precision oncology is largely built on theories and visions rather than realisations. Identification 
of incoherent explanatory models as well as arbitrariness in current practices indicates fragility in 
the relationship between knowledge and theory, undermining the legitimacy of current theoretically 




of biological organisation comes into conflict with the linear monocausal explanatory model on 
which precision oncology is largely built. Moreover, it suggests limitations with regards to the 
precision obtainable in molecular categorisation, precise predictions, and the idea of categorical 
“molecular targets”. The public discourse suggests that substantial progress is anticipated to result 
from continued pursuit of precision oncology. This friction calls for careful thinking and informed 
reasoning on the topic of what precision oncology in its current form can and cannot be expected 
to deliver, both in science, medicine and society. For this explicit purpose I believe that conceptual 
frameworks founded on somatic mutation theory are inadequate. Further, the translational 
emphasis characterising precision medicine related research and the gradual shift from evidence to 
theory-based practices suggest that the imaginary of precision medicine contributes to the 
maintenance and validation of the theoretical frameworks on which the imaginary is built. In 
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2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia 
Acute myeloid leukemia (AML) and related neoplasms 
 
 
AML with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1




AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM  
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3);RBM15-MKL1  
Provisional entity: AML with BCR-ABL1
AML with mutated NPM1
AML with biallelic mutations of CEBPA
Provisional entity: AML with mutated RUNX1  
 
 
AML with myelodysplasia-related changes 
 
 
Therapy-related myeloid neoplasms 
 
 
AML, not otherwise specified 
AML with minimal differentiation  
AML without maturation  
AML with maturation  
Acute myelomonocytic leukemia  
Acute monoblastic/monocytic leukemia  
Pure erythroid leukemia  
Acute megakaryoblastic leukemia  
Acute basophilic leukemia  






Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis (TAM)  
Myeloid leukemia associated with Down syndrome 
 
 
Blastic plasmacytoid dendritic cell neoplasm 
 
 
Acute leukemias of ambiguous lineage 
Acute undifferentiated leukemia 
MPAL with t(9;22)(q34.1;q11.2); BCR-ABL1** MPAL with t(v;11q23.3); KMT2A rearranged MPAL, B/myeloid, NOS 
MPAL, T/myeloid, NOS 
 
 

















t(8;21)(q22;q22.1) - RUNX1-RUNX1T1  
inv(16)(p13.1q22) or t(16;16)(p13.1;q22) - CBFB-MYH11 
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow 1  




Mutated NPM1 and FLT3-ITDhigh1 
Wild-type NPM1 without FLT3-ITD or with FLT3-ITDlow 1, 7 
t(9;11)(p21.3;q23.3) - MLLT3-KMT2A2 




t(6;9)(p23;q34.1) - DEK-NUP214 
t(v;11q23.3) - KMT2A rearranged 
t(9;22)(q34.1;q11.2) - BCR-ABL1 
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2) - GATA2,MECOM(EVI1) 25 or del(5q); 27; 217/abn(17p) 
Complex karyotype3 
Monosomal karyotype4  






Frequencies, response rates, and outcome measures should be reported by risk category, and, if sufficient numbers are available, by specific genetic 
lesions indicated. 
*Prognostic impact of a marker is treatment-dependent and may change with new therapies. 
1. Low, low allelic ratio (<0.5); high, high allelic ratio (</=0.5); semiquantitative assessment of FLT3-ITD allelic ratio (using DNA fragment analysis) 
is determined as ratio of the area under the curve “FLT3-ITD” divided by area under the curve “FLT3- wild type”; recent studies indicate that AML 
with NPM1 mutation and FLT3-ITD low allelic ratio may also have a more favorable prognosis and patients should not routinely be assigned to 
allogeneic HCT. 
2. The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations. 
3.Three or more unrelated chromosome abnormalities in the absence of 1 of the WHO-designated recurring translocations or inversions, that is, 
t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1. 
4. Defined by the presence of 1 single monosomy (excluding loss of X or Y) in association with at least 1 additional monosomy or structural 
chromosome abnormality (excluding core-binding factor AML). 
5. These markers should not be used as an adverse prognostic marker if they co- occur with favorable-risk AML subtypes. 
6. TP53 mutations are significantly associated with AML with complex and monosomal karyotype. 
7. When without adverse-risk genetic lesions 
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